# HSEF Review: α-Synuclein neurotoxicity and Parkinson disease neuronal loss ## AT A GLANCE **α-Synuclein can cause neuronal injury in experimental systems, and SNCA causes familial disease; direct misfolded-species causation of neuronal loss in typical sporadic Parkinson disease remains incompletely isolated.** > **Provenance:** 65 primary sources (65 Tier A) · 65 source-linked claims verified · 0 unverified · 0 contradicted · 25 partial full-text examinations · 40 abstracts/status records · **Structural gate: passed (0 fail; 1 justified conjunction warning)**. > **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-06. 0 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: **Approved as revised.** | HSEF Level | Confidence | Role of Mechanism | Momentum | Stability | Divergence | |---|---|---|---|---|---| | **Γ — Mechanistically plausible, partial system support** | Moderate | epiphenomenon, operationally at the full human causal scope | Decisive work underway | Uncertain | Mild overstatement (+1 rung in the representative framing examined) | - **The experiment that decides it:** selective removal and matched reinstatement of a defined harmful conformer, preserving normal α-synuclein function, changes independently measured dopamine-neuron survival; a validated human causal instrument must then connect that dependence to typical sporadic PD. - **What the field believes vs. what the evidence shows:** representative primary-trial framing invites at least Δ-level causal interpretation; the complete direct-toxicity/human-loss claim remains Γ, despite Ζ-level familial gene biology. - **Best-supported rival models:** heterogeneous PD pathways and organellar/clearance vulnerability tie as broader explanations of the shared dissociations; neither has an exclusive complete human execution mechanism established here. *Rubric: 01-neurodegeneration · HSEF v5.3 · 2026-10-03 · Fresh independent review; earlier website scores not consulted · Not a completed blinded calibration run.* ## Scorecard detail | Field | Value | |---|---| | Overall HSEF level | Γ — Mechanistically plausible, partial system support | | Confidence | Moderate | | Role derivation | Framework step 2 at full human misfolded-species/direct-loss scope; this operational label means unresolved causal dependency, not proved biological harmlessness | | Subclaims | Four unconditional preregistered causal subclaims | | Aggregation | Scope-matched; SC4 carries the full typical-human-PD claim | | Alternative rules | Weakest-link Γ; primary-subclaim SC3 Γ; scope-matched SC4 Γ | | Competing models | Five; leading rivals tied, nominal rank 3 | | Flagged perturbation reports | 16 evidence items in their actual scopes, including native biology and constrained models; repeated reports are not independent causal lines | | Access | 25 focused partial full texts, 40 primary abstracts/metadata; no complete-paper/supplement audit claimed | | Publication cutoff | 2026-10-03 | | Validation | Exact archived v5.3 validator: PASS; 0 fail, 1 justified warning, 31 pass | ### Subclaim score matrix | ID | Subclaim | Type | Scope | Rubric | Score | Confidence | Governing rule | |---|---|---|---|---|---|---|---| | SC1 | Endogenous changes in SNCA dosage or sequence cause a dopaminergic degenerative disease phenotype through α-synuclein biology. | mechanism | Human familial SNCA-linked dopaminergic degenerative disease; established coding variants and dosage gains considered individually. | 01-neurodegeneration | Ζ | High | Ζ convergence at familial gene-level scope | | SC2 | Identified misfolded α-synuclein species directly injure dopaminergic neurons, distinguishable from altered normal function, mere marking and exclusively indirect glial toxicity. | mechanism | Disease-relevant dopaminergic neuronal systems, with patient-derived, endogenous animal and artificial exposure scopes explicitly distinguished. | 01-neurodegeneration | Γ | Moderate | Γ system/scope and mediator-attribution boundary | | SC3 | Selectively changing misfolded α-synuclein accumulation changes dopamine-neuron survival or disease progression, with target engagement and specificity controls. | mechanism | In-vivo PD-relevant contexts; native-toxin/forced-seed model evidence distinguished from clinical human PD. | 01-neurodegeneration | Γ | Moderate | Γ system/scope and mediator-attribution boundary | | SC4 | The direct misfolded-protein mechanism accounts for dopaminergic neuronal loss in typical human sporadic PD, rather than only familial or imposed-expression/seeding systems. | generalization | Typical human sporadic PD; gene, olfactory and baseline-seed subgroups described without removing null participants retrospectively. | 01-neurodegeneration | Γ | Moderate | Γ system/scope and mediator-attribution boundary | **Aggregation preregistration.** Before evidence examination, the supplied scope-matched rule was retained. SC4 is the full direct-toxic-species/causal-neuronal-loss claim in typical human sporadic PD. A higher narrow familial or model result does not match that complete scope. The index's necessary-and-sufficient-primary-driver and extracellular-spread clauses are stronger than the user's statement and were not imposed. **Derivation.** SC1 Ζ, SC2 Γ, SC3 Γ and SC4 Γ give overall Γ through scope-matched SC4. Weakest-link and the preregistered primary-subclaim sensitivity SC3 also return Γ. Agreement of these arithmetic results does not make the causal premises interchangeable. ## Competing mechanistic models ### M5 — Heterogeneous PD pathways Distinct genetic, cellular and pathological routes converge on nigral vulnerability, with α-synuclein a context-dependent contributor. Explains baseline-genotype and seed/inclusion heterogeneity without requiring one executioner in every patient. Familial alternative etiologies are causal within their own scopes, but the broad multi-pathway execution model is not a single demonstrated human mediator mechanism. Strongest support: [11], [18], [17], [13]. Strongest constraint: [1], [2], [43]. **Rank 1; Γ — Mechanistically plausible, partial system support.** ### M3 — Mitochondrial/lysosomal and proteostatic failure Cellular dopamine/organellar/clearance failure contributes to injury and can promote α-synuclein accumulation as a mediator or response. Explains genotype, dopamine vulnerability and clearance dependencies, and permits α-synuclein injury downstream. It does not establish uniform organellar primacy across human PD; reciprocal protein–organelle feedback remains unresolved. Strongest support: [29], [33], [11], [14]. Strongest constraint: [1], [3], [43]. **Rank 1; Γ — Mechanistically plausible, partial system support.** ### M1 — Direct misfolded α-synuclein toxicity Misfolded α-synuclein is directly neurotoxic to dopaminergic neurons, and its accumulation causes the neuronal loss of Parkinson's disease. Direct injury is experimentally possible and human SNCA biology is causal in familial disease. The species responsible, concentration, native-function effects and typical-human-PD mediation remain unresolved; primary antibody nulls constrain clinical extrapolation without disproving intracellular toxicity. Strongest support: [27], [26], [30], [43]. Strongest constraint: [38], [24], [55], [54]. **Rank 3; Γ — Mechanistically plausible, partial system support.** ### M2 — Inclusion sequestration can protect Some aggregation or inclusion formation sequesters harmful soluble protein/material, so total visible burden need not equal toxic exposure. Protective fibrillar action is demonstrated against one catechol exposure in culture; human sequestration remains a cross-sectional interpretation. Inclusion maturation can damage organelles. A protective storage account cannot be generalized to every Lewy inclusion or every fibril; the sign depends on species, state and cell context. Strongest support: [50], [19]. Strongest constraint: [32], [27], [26], [30]. **Rank 4; Γ — Mechanistically plausible, partial system support.** ### M4 — Glial/non-cell-autonomous toxicity Host inflammatory or glial responses contribute to injury rather than all loss arising solely through direct neuron-intrinsic toxicity. Inflammation after native protein suppression, glial aggregates and glial susceptibility motivate non-cell-autonomous contributors. They do not selectively perturb the glial-to-neuronal injury dependency; receptor-route results are not uniquely glial evidence. Direct neuronal assays show an exclusively indirect account is insufficient. Β reflects the examined broad glial-execution premise's association/host-response evidence rather than an asserted glial causal mechanism. Strongest support: [35], [45], [32]. Strongest constraint: [43], [27], [26]. **Rank 5; Β — Associational.** ### Tournament result Heterogeneity and organellar/vulnerability accounts tie at rank 1 because they accommodate genotype, cellular state and burden/outcome dissociations while allowing direct α-synuclein injury in some settings. The nominal is rank 3 as a plausible component whose complete sporadic causal attribution remains unresolved. These are comparative explanatory judgments, not a formal likelihood or quantitative model-selection exercise, and they do not alter the nominal Γ score. No single experiment separates the tied leading rivals. PRKN autopsy findings constrain a universal visible-Lewy executioner; patient-derived neurons with isogenic SNCA dose correction establish a direct experimental susceptibility route. Neither uniquely selects a complete human mechanism. The protective-aggregation competitor is also bounded: a protective response to one catechol exposure does not establish that mature Lewy bodies protect in all PD, and organelle-containing inclusion maturation can itself be harmful. [11], [43], [50], [32] ## Full review ### Claim restatement and hypothesis parsing **User statement, preserved:** “Misfolded α-synuclein is directly neurotoxic to dopaminergic neurons, and its accumulation causes the neuronal loss of Parkinson's disease.” **Graded claim:** the same statement. It is a causal conjunction: direct toxic capability and a causal account of actual human neuronal loss. It does not explicitly require every case to have one mechanism, extracellular transmission to be necessary, visible Lewy bodies to be toxic, or misfolded protein to be necessary and sufficient for every PD phenotype. The full typical-human-PD clause must nevertheless be supported at that scope rather than inferred wholly from rare familial or artificial systems. The mechanism can be intracellular and can act through membranes, mitochondria, dopamine chemistry or protein clearance; these mediators do not make toxicity indirect by definition. A purely glial-mediated process is a different explanation of directness. Four preregistered claims separate familial gene-level causality (SC1), defined-species direct injury (SC2), causal intervention on misfolded accumulation (SC3) and the complete mechanism in typical sporadic human PD (SC4). The descriptive presence of α-synuclein in Lewy pathology and diagnostic seed positivity is auxiliary evidence, not a shortcut to a causal grade. ### Field classification and rubric routing The neurodegeneration rubric governs all four subclaims and the broad competitors. Its core principle asks about temporal order, selective vulnerability, progression and intervention response; spread is relevant only where a particular experiment relies on it. No obligatory endogenous propagation premise is added to this direct-toxicity review. Gene-level human natural experiments are field-valid equivalents, while cultured toxic species, imposed seeds and imaging/fluid signals carry their actual inference limits. ### Evidence inventory and causal analysis The review examined 65 distinct primary reports, with source-specific result and limitation cards below. These are report counts. PASADENA's primary, subgroup and open-label-extension articles are one underlying randomized study; SPARK's efficacy and biomarker articles are one study. Cinpanemab's later CSF-binding assay uses its phase 1 cohort. The Iowa and French SNCA reports include family recharacterizations, and PPMI contributes participants or components to several SAA reports. Laboratory replication and multiple readouts raise confidence without automatically adding independent causal lines. #### Familial SNCA establishes gene biology, not the lethal conformer Segregating A53T, E46K and G51D coding variants, together with independently confirmed wild-type locus duplication/triplication, establish a causal role for SNCA biology in familial dopaminergic degenerative disease. Sequence and dosage perturbations narrow different errors: mutation-specific effects cannot explain wild-type dosage disease, while a shared neighboring-gene multiplication cannot explain independent coding-change families. Expression and copy-number confirmation strengthen the instrument. This supports SC1 Ζ without assuming that all carriers have identical onset, that every nominated variant is pathogenic, or that the molecular executor is known. [1], [2], [6], [3], [4], [5], [23] The dosage observations contain their own cautions. Iowa fine-mapping describes a multigene interval, and the expanded French duplication report also covers other genes. H50Q was originally nominated in one case, but a population/case-control analysis found no enrichment and judged pathogenicity insufficient. UK Biobank copy-number events without diagnosed PD include suspected mosaicism and uncertain observation-time/brain-expression relevance. Those results constrain indiscriminate variant/penetrance claims while leaving well-supported familial alleles intact. They do not establish misfolded-species mediation. [9], [10], [7], [8], [24] #### Direct toxic capability depends on species, dose and cell state Oligomer-prone versus rapidly fibrillizing sequence variants produced differential dopaminergic injury in the Winner study; prefibrillar variants were toxic across the Karpinar systems. These are more than co-occurrence, but engineered sequence can change membrane interactions or ordinary function as well as conformation, and expression/exposure differs from spontaneous human biology. Structural membrane-insertion studies and release of oligomers from fibrils explain possible direct injury routes without making “oligomer,” “fibril,” “seed” and “Lewy body” interchangeable substances. [26], [27], [47], [48] The patient-neuron strain experiment is a particularly strong cell-system discriminator. Amplified PD/MSA seeds caused progressive injury in SNCA-triplication dopamine neurons, and isogenic dosage correction rescued the vulnerability; healthy-control cells did not show the same later toxicity despite comparable early seeding. Monomer and diluted-homogenate comparisons support an assembly-dependent route. The result establishes positive direct toxicity in a specified human cell context. It remains culture plus amplified-conformer exposure, and dose correction changes normal protein amount as well as the misfolding substrate. It does not by itself establish identical injury at normal SNCA dose in typical sporadic PD or an organismal native toxic-species dependency. [43] Dopamine and calcium further qualify directness. Human dopaminergic versus cortical cultures and native Snca-null midbrain cultures showed dopamine-dependent vulnerability. α-Synuclein can therefore contribute to injury initiated through dopamine/oxidative or calcium stress rather than having to be the sole initiating cause. These interactions are compatible with direct intracellular toxicity and with organellar/proteostatic models; they do not identify one naturally accumulated conformer as the human executor. [28], [29] #### Native α-synuclein interventions establish real contextual biology Native Snca deletion protected mice from MPTP, and partial native knockdown protected rotenone-exposed rat nigral systems. Those are positive field-valid perturbations of total α-synuclein biology within their toxin models, rather than mere biomarkers. They can support model-scoped Δ and context-specific Ε for that native protein dependency. MPTP resistance also involved altered complex-I toxin action, and total knockdown changes physiological protein functions and aggregation substrate simultaneously. These positive results are retained; they do not satisfy SC3's selective misfolded-accumulation attribution simply because total protein is involved. [34], [36] Other native suppression experiments caused nigrostriatal damage and partial protein re-expression rescued it, whereas a long-term delivery context produced no Nissl-defined loss despite declining TH signal with both vectors. These findings identify dose, delivery and ordinary protein-function dependencies. They refute a casual assumption that reducing any α-synuclein signal must be beneficial, but they do not refute selective removal of a harmful conformer. They also show why TH marker loss cannot automatically be treated as neuronal death. [49], [35], [37] ASO treatment reduced pathology and preserved TH-positive counts in PFF models, with dopamine preservation in some conditions. A transient post-seed regimen later preserved TH despite an increased aggregate count; striatal dopamine was unchanged in that comparison. Thus, a lower visible aggregate count is not invariably the mediator of a functional marker benefit. The examined stereology is TH-based, so the review does not relabel every estimate as independently verified neuronal survival. [38] The anle138b MI2 study is also a positive intervention, not merely an association. It changed dense aggregate distributions and restored dopamine release/gait in a truncated 1–120 transgene model on a Snca-null background; baseline cell loss was independently NeuN-confirmed. It is not described here as automatically massive overexpression: the report compares expression with native protein and finds lower expression in some examined regions. Treatment rescue counts were TH-based. Crucially, its Discussion leaves open whether benefit arose from reduced aggregate toxicity or more physiologically active small species. The blocker is that specific mediator distinction plus artificial substrate and pharmacological alternatives, rather than a blanket forced-transfer cap. [41] PFF inoculation into native-recipient mice and patient-extract injection into primates show that pathological material can initiate nigrostriatal degeneration in vivo. They do not establish spontaneous human initiation or isolate exclusively direct neuron-intrinsic action from uptake, immune or extract-cofactor effects. Intravenous PFF/delivery-peptide injury and region-level expression dissociation likewise do not constitute native gene absence. Native-substrate seeding is not overexpression, and the universal forced-transfer cap is explicitly about endogenous propagation claims; here the relevant limitations are imposed initiation, mediator specificity and the claimed human scope. [30], [44], [46] Mao's global Lag3 knockout is a genuine positive model-survival perturbation: after PFF exposure it preserved both TH-positive **and Nissl-positive** nigral neurons, dopamine and motor performance. Cultured knockout/re-expression tests also connect uptake and toxicity. The in-vivo LAG3 dependence of PFF injury can therefore cross a model-scoped Δ. SC3's complete mediator premise remains unresolved because global LAG3 manipulation also changes immune biology and uptake, while the in-vivo protection is not separated by a neuron-specific or mediator-matched reinstatement. The neuronal-expression and different-context null study narrows interpretation but is not a matched replication of the nigrostriatal experiment. The result is not dismissed as biomarker-only or null merely because seeds were supplied. [39], [40] The 2025 primate study reuses previously characterized patient fractions and a prior 24-month observation component while adding earlier time points and proteomics. It is one useful expanded experimental program, not an independent new primate replication. Its human-origin material does not eliminate extract, exposure or host-state confounding. [44] #### Human pathology and seeds diagnose biology without proving execution Lewy pathology includes crowded membranes and organelles, while proximity-ligation studies detect non-inclusion signal. This cautions against reading an inclusion stain as a complete toxic-species census. In the 2025 LRRK2 study, the six Lewy-negative variant cases comprise **three clinical PD cases, one PSP case and two people without clinical neurodegenerative diagnoses**; they are not six comparable PD cases. Non-inclusion signal was detected, but neuronal loss was not quantified. That finding prevents equating Lewy negativity with absence of all misfolded material, without proving that the detected signal killed dopamine neurons. [13], [19], [18] The 2024 cortical proximity-ligation series contrasts anterior-cingulate Braak IV and VI pathology, with similarly long clinical disease durations. Stage IV is not automatically a temporally early PD cohort; sequestration/timing is inferred cross-sectionally rather than observed longitudinally. The assay has its own species-specific validation limits, so a human signal and a mouse signal are not assumed identical measurements. [19] PRKN and LRRK2 autopsies show severe or clinically relevant nigral degeneration with sparse/absent conventional Lewy inclusions. These are important boundaries for a visible-inclusion necessity claim. They are not proof of absent earlier soluble misfolding or of an α-synuclein-independent mechanism in every sporadic case. Conversely, GBA case-control/autopsy and somatic SNCA copy-gain associations extend relevance to ordinary disease but do not supply a selective misfolded-mediator instrument. PARK2-null human cultures can form seeding-competent α-synuclein despite the familiar Lewy-negative parkin autopsy pattern; no α-synuclein-selective death rescue in that experiment establishes the mediation. [11], [12], [14], [15], [16], [45] The large PPMI SAA study identifies substantial baseline subtype variation and positivity before diagnosis in some prodromal participants. Kinetic follow-up associates faster amplification with cognitive decline, rather than establishing all progression outcomes or dopamine-neuron loss. The 2026 Norwegian report has a large genotyped cohort but a much smaller actual CSF-SAA subset. The 2026 global clinicopathologic study informs diagnostic accuracy, incidental pathology and copathology. These findings are informative about timing, classification and heterogeneity; assay kinetics and seeding competence are neither a validated quantitative brain toxic dose nor a causal neuron-killing assay. [17], [20], [21], [22] #### Human interventions: efficacy, engagement and mediation remain separate PASADENA did not meet its primary global clinical endpoint or show a substantial dopamine-transporter imaging difference. Its subsequent baseline-defined subgroup analyses reported larger numerical motor effects in groups expected to progress faster, but remain exploratory after a failed primary endpoint. The open-label extension favored treated participants over an external PPMI comparator, while the report itself acknowledges lack of concurrent placebo, medication/cohort issues and incomplete imaging matching. These are real primary analyses, counted as reports from one study, and are not presented as independent randomized efficacy confirmations. [51], [52], [53] SPARK found no clinical or DaT-SPECT benefit and stopped for lack of efficacy. Its biomarker report found no treatment effect across the measured fluid/imaging biomarkers, despite high baseline seed positivity in the CSF subgroup. The later phase 1 assay directly detects cinpanemab–α-synuclein complexes in human CSF, correcting an absolute assertion that central engagement was never measured. That is not evidence that the same trial selectively cleared the intracellular toxic species, and the phase 1 reassay is not a second independent clinical experiment. [55], [56], [64], [62] The published 2026 PADOVA primary report randomized 586 participants and **did not meet its primary endpoint**: HR 0.84, 95% CI 0.69–1.01, p=0.066. The authors report prespecified exploratory signals and support continued testing; the favorable estimate is not dismissed as zero activity, but it is not converted into a positive primary trial or direct neuroprotection proof. Its linked correction states that the appendix was corrected as of 2 July 2026. The body of that notice was read, while the corrected appendix was not; what changed and its detailed scientific impact remain unresolved. The notice attaches to this source and is not counted as another trial report. [54] Phase 1 PRX002, Lu AF82422 and MEDI1341 demonstrate peripheral and/or central-compartment exposure, binding or free-signal modulation with useful safety information. MEDI1341's high-dose PD group had a median 59.0% decrease in the CSF-free signal at Day 85. Binding/sequestration can lower a free assay signal without demonstrating total pathogenic tissue removal; no confirmed clinical trajectory benefit follows from these small pharmacodynamic studies. [63], [65], [60], [61] PD01A and PD03A generate antibody responses, while UB-312 reports CSF antibodies in a subset and an exploratory SAA-fluorescence reduction in one randomized active-dose group. Randomized UB-312 groups did not differ statistically on clinical scales. The unplanned comparison of post-treatment CSF-antibody-positive versus negative participants does not preserve randomization and cannot define the population to which the original claim applies. The source also states that SAA is not validated as a quantitative measure and conversion from fluorescence to misfolded amount is unknown; antibody spiking changes assay kinetics. These results support continued work while leaving efficacy and toxic-species mediation separate. [58], [59], [57] ### Verification, editorial notices and access 65 bounded source-linked result claims were checked against actually retrieved primary records. 25 records received focused Methods/Results and/or Discussion examination; 40 remain abstract/status-metadata examinations. Numerical clinical statements in this review are present in the examined primary abstracts or focused text, with ledger access depth explicit. Full texts merely downloaded are not counted as read, and no complete tables/figures/supplement audit is claimed. Tier A status does not convert abstract access into full-text verification. SciSpace supplied semantic discovery; its clinical extraction column returned **0/3 extractable records**. It did not provide a general full-text reader. PubMed/Entrez, Europe PMC and primary publisher/registry sources supplied the independently examined records. Citation-context counts were not retrieved, not inferred to be zero. PubMed `none_found` means no linked adverse notice was found in the bounded record check, not exhaustive publisher-integrity clearance. PADOVA's corrected-appendix limitation remains explicit. ### Cap rules applied and precedence **SC1 — Familial native gene biology.** The familial-to-sporadic constraint is scope restriction: “Genetic evidence in familial / syndromic cases generalized to sporadic disease is scope-restricted.” The rare familial native-genotype causal result is not reduced by an association cap. It reaches Ζ for its own claim, while the specific conformer and sporadic disease mechanism remain separate. **SC2 — Identified-species direct injury.** “Overexpression in model systems caps at Γ” binds inference from ectopic variant expression, and “In vitro evidence alone cannot exceed Γ.” binds the direct cultured-human toxicity/rescue leg. Native protein-dependent toxin vulnerability and imposed-material in-vivo injury are preserved as real contextual results but do not isolate the stipulated specific misfolded mediator while excluding ordinary function and solely indirect injury. **SC3 — Selective accumulation intervention.** “Biomarker change without functional/phenotypic change caps at Γ.” binds human free-CSF/binding/seed-assay engagement studies. Native total-protein interventions may cross model-level Δ or Ε for the protein dependency they actually manipulate. The generic SC3 assertion remains Γ because the model benefits do not jointly isolate harmful-species change and the asserted survival/trajectory mechanism with specificity controls. The MI2 pharmacology result is explicitly evaluated for its physiological-small-species alternative rather than labeled overexpression solely because it uses a transgene. **SC4 — Full human generalization.** “Pure association evidence — however large, however replicated — cannot exceed Β.” governs isolated human pathology/GWAS/seed-assay claims. It is not applied again to the combined mechanistic set. Familial natural experiments support gene-level causality, and cell/conformer work establishes mechanistic injury capability, supporting Γ overall; the missing specific human causal instrument prevents a larger score. The universal statement “Seeding or forced-transfer paradigms cap at Γ” is specified for endogenous propagation claims. It is not a blanket cap against every experiment concerning direct toxicity. ### Β/Γ/Δ boundary check The governing rubric requires: **“Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.”** Its field-valid perturbations include **“Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo”** and **“Selective pathway inhibition that changes onset/progression while preserving broader viability.”** A qualifying design must return a positive result for the claim being scored; a null trial does not cross Δ just by being randomized. **SC1:** segregating pathogenic coding changes and dosage gains are positive endogenous human natural experiments with disease phenotypes. The in-vitro/forced-seed hard rules do not define this evidence set, so the Δ boundary is crossed. The distinct coding/dosage errors support upward testing. **SC2:** direct injury and matched gene-dose correction are positive within examined cultured/engineered contexts. No selected experiment jointly supplies an endogenous, species-resolved organismal direct-injury dependency and the specificity controls at the subclaim's biological scope. This leaves Γ without asserting that all toxin models are mere association. **SC3:** endogenous total-SNCA suppression/deletion can protect or injure nigrostriatal systems; aggregation-profile pharmacology has positive functional results in MI2; global LAG3 deletion has actual Nissl-confirmed survival and motor benefits after PFF exposure. Those are causal contextual programs. The harmful misfolded-material intervention remains entangled with normal protein function or global immune/uptake effects; cultured rescue does not resolve the global in-vivo instrument. Several other preservation estimates use TH alone. This specificity/mediation gap fixes SC3 Γ at its in-vivo model scope; missing human efficacy or spontaneous initiation is not its sole blocker. Human interventions provide the separately relevant SC4 limit. **SC4:** the familial instrument does not automatically identify direct sporadic misfolded-mediated loss. Positive clinical signals are exploratory or external-comparator findings, and phase 1 target engagement is biomarker-only. No qualifying positive perturbation or equivalently selective human natural experiment establishes the complete direct-conformer-loss claim. Γ is the boundary result. The rubric's hard-rule list is examined verbatim: **“In vitro aggregation alone”** and **“In vitro seeding alone”** do not describe the complete evidence set because actual injury/function outcomes were studied; **“Droplet aging in vitro”** and **“Organoid toxicity without organismal follow-through”** are not the selected evidence base; **“Exogenous seeding models alone”** does not erase the native-genotype or toxin findings, but identifies a restricted imposed-initiation leg. Whole-claim ceilings follow the actual mediator and scope limits above, not automatic firing on one limited leg. ### Threshold testing **SC1:** Δ is crossed by native human SNCA natural experiments. Ε — **“Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.”** — is satisfied for genotype-defined familial disease with variable penetrance/phenotype. Ζ requires **“Multiple independent causal lines in vivo,” “Replication across at least two relevant systems,”** and **“Narrowing of major alternative models.”** Distinct human coding-change and wild-type dosage natural-experiment systems meet that gene-level requirement while excluding different assignment errors. They are not merely re-reports of the Iowa family. Η is not established: no examined selective human SNCA rescue/withdrawal establishes intervention-sensitive disease-trajectory correction in this familial scope, and the remaining locus/penetrance issues are not resolved. The cumulative Θ and Ω requirements cannot be reached without first satisfying Η; neither universal prediction nor necessity/sufficiency is asserted. **SC2, SC3 and SC4:** the first unmet complete-claim threshold is Δ. To cross it, a positive matched-control manipulation must isolate a defined harmful misfolded species, verify relevant exposure/engagement and show direct dopamine-neuron survival or meaningful sustained disease change, without attributing benefits solely to normal protein function, TH regulation or general host effects. Gene-level total-protein/toxin and engineered-context Δ/Ε effects are explicitly retained and are not scores for the full premises. For SC4, the positive instrument must materially address typical human sporadic biology rather than only a cultured familial genotype or imposed seed model. **Generalization:** genotype, normal-dose/isogenic cell contrasts, toxin response and assay-defined cohorts map real context boundaries. These can warrant Ε for the corresponding contextual biological mechanism rather than being called “weak” merely because generalization fails. They do not substitute for SC4's full causal claim. SAA-negative or nonresponsive participants remain visible; a post-treatment response cannot define a new enrolled scope. ### Falsification patterns and pitfalls The five rubric patterns are assessed without counting missing proof twice: - **“Blocking the proposed mechanism does not alter onset/progression in vivo.”** Primary trial nulls constrain extracellular antibody strategies. Effective removal of the specific intracellular direct-toxic mediator is not demonstrated, so the full pattern is not triggered and no second downgrade is applied. - **“Pathology still initiates in its absence.”** Lewy-negative autopsy is not absence of all harmful species. The user did not state a visible-inclusion necessity claim; this does not trigger a downgrade for the exact claim. - **“The claimed temporal order is not reproducible.”** Cross-sectional pathology cannot establish a universal temporal sequence; prodromal seed positivity does not prove initiation. No specific experimentally disproven temporal prediction of the supplied claim is identified. - **“Alternative models explain the same findings more parsimoniously.”** The tournament exposes compatible alternatives, but no exclusive discriminating experiment demonstrates their sole human execution mechanism. Ranking is not falsification or a grade change. - **“Subtype heterogeneity shows the mechanism is non-general but the hypothesis is framed as general.”** The broad sporadic mechanism remains incompletely established, with genotype/assay boundaries disclosed. The selected data do not prove absent direct α-synuclein contribution in typical sporadic disease. The scope limit is counted through SC4, without strengthening the user claim into uniform necessity and downgrading it for that stronger premise. No formal falsification tier downgrade is applied beyond these cap/threshold determinations. Specific pitfalls are **2. Association dressed as mechanism**, **3. Overexpression treated as endogenous mechanism**, **8. Confirmation by biomarker**, **10. Mechanism conflation**, **11. Intervention specificity assumed rather than demonstrated**, **16. Failed generalization mistaken for weak evidence**, **17. Negative field-valid perturbation read as a crossed threshold**, **18. Causal-evidence tallies that do not survive an audit**, **21. A universal cap re-applied to a convergent evidence set**, and **22. Scope fitted to the result**. Their concrete triggers are the pathology-to-death inference, total-versus-misfolded protein manipulation, TH-versus-survival readout, exploratory-response subgroup and cohort/model reuse discussed above. **Causal tally:** 16 inventory items flag perturbation reports in their stated native or constrained model scopes, including opposing results. The audit retains 15 endogenous-dependency reports and excludes MI2's artificial truncated-substrate intervention from that native tally while preserving its positive functional finding. These include repeated family reports and imposed-model dependencies; they are not 15 independent positive human-toxic-species causal investigations. The number of qualifying positive complete-SC4 selective survival dependencies is zero in this inventory. Ectopic variants and biomarker-only engagement are not added to that stronger tally. The ledger distinguishes report count, study grouping and the two causal-assignment lines supporting only SC1. ### The steelman **The case for Δ, one rung above, is written first.** Human SNCA genetic causality, conformer-specific direct injury, isogenic patient-neuron rescue, native protein-lowering protection and positive aggregation pharmacology form an orthogonal case that α-synuclein can be a contributing toxic driver. This does not need every case to be exclusively α-synuclein-driven or extracellular spread to be necessary. PADOVA's favorable estimate and exploratory prasinezumab effects are compatible with a contribution. On that interpretation, this is already a first causal perturbation rather than merely plausibility. **The case for Β, one rung below.** Actual sporadic-human observations are mostly pathology, seed diagnosis or cohort associations; familial mutations can have different biology; and the primary clinical antibody trials have not confirmed disease modification. The complete direct-toxic-human-loss assertion could therefore be treated as association. **Rejected, and why.** Δ is blocked by the missing specific endogenous mediator/survival instrument: global protein biology, imposed conformers, TH preservation and exploratory clinical efficacy do not jointly establish direct misfolded-species execution of typical human neuronal loss. Β understates reproduced direct injury and context-sensitive rescue capability. Γ retains those biological results while exposing the missing complete dependency. #### Upper-ladder check Human genetics and dose/phenotype natural experiments were considered and support SC1 Ζ; they were not re-capped because pathology is also present. No valid misfolded-species mediation instrument or cross-population toxic-dose experiment was examined for SC4. Native knockdown/re-expression tests alter ordinary protein function as well as substrate. Human targeted therapies were examined with primary clinical outcomes, but the primary reports are null/suggestive rather than confirmed positive, while free-CSF or antibody binding is not species-resolved brain clearance. The upper ladder does not require an unethical RCT: an adequately specific natural experiment could also cross it. The failure is mediator/scope attribution, not the mere absence of a particular trial design. ### Role-of-mechanism derivation The full human direct-toxic-species role is classified **epiphenomenon** by the framework's operational step 2: a disease-relevant causal dependency in either direction is not isolated at that complete scope. This label does not mean α-synuclein is biologically inert or that accumulated protein is proved harmless. Gene-level familial causality and model toxicity are established at their own scopes; reinforcing or initiating roles remain plausible in ordinary disease. A model-supported amplifier is not silently relabeled a demonstrated full-human role, and no tournament rank supplies causation. ### Momentum, Stability, Divergence **Momentum — Decisive work underway.** The live PARAISO registry NCT07174310 describes a randomized phase 3 prasinezumab/placebo trial and was checked on 2026-10-03: recruiting, last updated 3 September 2026, motor-event primary outcome with observation to at least week 104. It is a named clinical causal program, not a completed efficacy result or one of the numbered peer-reviewed sources. The current registry record is saved with this review. **Stability — Uncertain.** A confirmed primary clinical benefit with relevant pathogenic-species engagement and degeneration mediation could raise SC3/SC4. Adequate selective intracellular toxic-species depletion without disease benefit could lower the direct contribution claim. PARAISO's estimated primary completion is 30 June 2029, not a guaranteed result date. A symptom-only benefit or extracellular-antibody null without mediator engagement would not alone settle the exact direct intracellular claim. **Divergence — Mild overstatement.** The representative PD01A driver framing and PASADENA/SPARK pathogenic-role backgrounds invite an implied Δ causal reading; assessed Γ gives **Δ − Γ = +1 rung**. This is a bounded interpretation of named primary-report framing, not a poll of the field. Primary investigators also explicitly caution that exploratory signals require confirmation. M/S/D are assigned after the score and modify neither score nor confidence. [58], [51], [55] ### Final adjudication **Γ — Mechanistically plausible, partial system support; Moderate confidence.** Scope-matched aggregation selects SC4 Γ for the full direct-toxic-species/human-neuronal-loss claim. Familial SNCA biology retains SC1 Ζ; SC2 and SC3 remain Γ for their complete stipulated mediator premises, with narrower positive cell/model effects described explicitly. The score is not higher because no examined perturbation or equivalently selective human natural experiment separates the harmful conformer from normal protein function and connects its effective change to independently measured dopaminergic survival in typical sporadic PD. It is not lower because direct injury and controlled susceptibility/rescue capabilities exist beyond association. A positive specific biological/clinical instrument would raise the relevant subclaim; a properly engaged direct-toxic mediator null would challenge it. The present evidence supports continued causal investigation without declaring either universal toxicity or definitive harmlessness. ## Proposed decisive experiments ### Endogenous conformer depletion with matched reinstatement Selectively remove a defined harmful conformer at physiological protein expression, retaining normal synaptic α-synuclein function; then restore that conformer without increasing total protein or injuring proteostasis generally. Measure orthogonal conformer engagement, prospective dopamine-neuron lineage survival, pan-neuronal counts, dopamine physiology and sustained function. The critical controls are inactive reagent, equal physiological protein, a nontoxic assembly rescue and blinded exposure/timing. Effective removal with no survival effect would falsify the proposed direct contribution in that context; matched restoration of injury only by the harmful conformer would support it. ### Controlled human engagement and degeneration mediation Preregister baseline genotype, seed and clinical strata without treatment-defined responders. Randomize a strategy that demonstrably engages the proposed harmful intracellular or extracellular entity and preserves ordinary protein function, over an adequate clinical horizon. Measure the primary disease trajectory, independently validated degeneration and mediator engagement separately, addressing symptoms, inflammation and general protein lowering. Free-CSF assay signal and SAA fluorescence must be validated before being interpreted as quantitative brain conformer depletion. A replicated primary degeneration/trajectory effect attributable to the specific mediator would cross the relevant human boundary; verified depletion without benefit at adequate exposure would challenge it. ## Knowledge gaps - **Toxic entity and kinetics:** oligomers, short fibrils, seeds, inclusion maturation and insoluble burden interconvert and need not have the same toxic sign. - **Physiological function:** suppression can protect or harm depending on context; restoration of ordinary protein function can mimic a benefit attributed solely to aggregate removal. - **Human survival mediation:** clinical motor scores, DAT/TH signals, seeds and pathology do not independently measure the same loss process. - **Access and grouping:** the corrected PADOVA appendix and exact global participant overlap were not fully audited; those limits restrict detailed methods and independence claims. ## Reviewer notes The exact v5.3 archive and its unmodified validator are retained. Source archive SHA-256 is recorded in `framework/METHODS_AND_VERSION.md`; the inner historical directory name does not change the version. Both `scope` and `claimed_scope` are emitted on each subclaim to resolve the archive's template/validator mismatch. A structural validator pass checks consistency and required fields, not scientific correctness, clinical efficacy or inter-reviewer reliability. This fresh review did not consult prior scored website reviews and is not a completed blinded calibration run. The validator's `v5.claim_form` warning is explicitly justified: `entry_form` is recorded as conjunction because the exact user wording joins direct toxicity and human causal loss. It remains a gradeable causal proposition, not a topic, phenomenon or question; four unconditional subclaims and preregistered aggregation grade both causal premises. The wording is retained rather than silently strengthened or weakened to suppress a structural warning. The user wording, preregistration and sequential review order govern. No public site file, existing score or deployment is changed by these local artifacts. Grade judgment rests on actually examined primary reports with explicit scopes and access depth, not on SciSpace search hits, reviews counted as primary, or conference-only outcomes. The clinical correction and current registry supplement are retained separately. A correction notice is attached to its parent source rather than counted as an additional study. ## Complete evidence cards ### E01 — Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. **Source:** [1] · PMID 9197268 · natural experiment · Strong · supports. **Scope:** SC1. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** An SNCA mutation was identified in a large Italian kindred and three Greek families with autosomal dominant Parkinson disease. The human segregation/natural-experiment result connects altered alpha-synuclein biology to inherited disease. **Inference limit:** It does not identify the neurotoxic conformer, isolate misfolding from altered normal protein function, or show that accumulation is the mediator of dopamine-neuron death in typical sporadic PD. **Confounders:** Variant segregation is a gene-level rather than species-selective perturbation; Rare inherited disease scope. **Study:** SNCA_A53T_ITALIAN_GREEK_KINDREDS_1997. Multiple reported kindreds support the coding-variant line; they are not four distinct mechanistic modalities. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E02 — The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. **Source:** [2] · PMID 14755719 · natural experiment · Strong · supports. **Scope:** SC1. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** E46K segregated in a Spanish autosomal dominant parkinsonism/dementia family: affected members and three young asymptomatic carriers had the variant, while examined controls did not. Autopsy showed severe substantia nigra atrophy and abundant alpha-synuclein Lewy pathology without Alzheimer pathology. **Inference limit:** Segregation plus pathology does not establish a particular misfolded species as the toxic mediator or demonstrate a selective rescue of degeneration by removing that species. **Confounders:** Age-dependent expression in young carriers; One family and mixed parkinsonism/dementia phenotype. **Study:** SNCA_E46K_SPANISH_KINDRED_2004. Independent coding kindred; one familial human line, not separate causal lines for genotype and pathology. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E03 — Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. **Source:** [3] · PMID 15451224 · natural experiment · Strong · supports. **Scope:** SC1. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** Screening nine autosomal dominant families found an SNCA duplication in one family, confirmed by fluorescence in situ hybridization. The phenotype was relatively late-onset and slowly progressive, contrasting with the previously described severe triplication phenotype. **Inference limit:** The comparison is not a controlled within-person reduction from triplication to duplication. Copy gain does not isolate aggregation from total protein abundance or neighboring genes. **Confounders:** Cross-family dose/phenotype comparison; Locus rather than misfolded-species perturbation. **Study:** SNCA_FRENCH_DUPLICATION_KINDRED_2004. French duplication family; Mutez 2011 appears to characterize a previously described French kindred, so conservatively grouped with this report pending full family identity verification. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E04 — Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. **Source:** [4] · PMID 15451225 · natural experiment · Strong · supports. **Scope:** SC1. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** Screening 119 people with familial Parkinson disease identified two SNCA duplications. Carriers had a phenotype resembling typical PD, rather than the fulminant triplication phenotype. **Inference limit:** Familial duplication does not show that measured misfolded accumulation mediates death, that Lewy bodies themselves are toxic, or that dosage explains ordinary sporadic PD. **Confounders:** Few duplication families; Copy gain can include other locus effects. **Study:** SNCA_IBANEZ_DUPLICATION_FAMILIES_2004. Two duplication family observations strengthen the dosage line; replication alone does not create a new mechanistic class. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E05 — Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. **Source:** [5] · PMID 15159488 · natural experiment · Strong · supports. **Scope:** SC1. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** In the Iowa triplication kindred, blood alpha-synuclein and brain SNCA mRNA were approximately doubled. Brain insoluble/aggregated alpha-synuclein was disproportionately increased relative to the net soluble signal. **Inference limit:** The inherited locus gain and postmortem biochemical readout do not isolate aggregation as the cause of neuron death or exclude effects of increased normally folded protein and co-amplified genes. **Confounders:** Postmortem survivor sampling; Co-amplified locus and total-protein change. **Study:** SNCA_IOWA_TRIPLICATION_KINDRED. Iowa kindred, shared with Zafar 2018 and foundational Singleton 2003; these reports constitute one dosage-family study group. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E06 — α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? **Source:** [6] · PMID 23404372 · natural experiment · Strong · supports. **Scope:** SC1. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** G51D segregated in a British family and was absent in more than 4500 controls; larger SNCA rearrangements were excluded. The autopsied proband had onset at 19, severe nigral and widespread neuronal loss, neuronal alpha-synuclein inclusions and MSA-like oligodendroglial inclusions. Tau and TDP-43 copathology were also present. **Inference limit:** The rare familial syndrome does not isolate direct neuronal toxicity from glial amplification, identify the lethal species, or explain ordinary sporadic PD. Minimal inclusions in the severely depleted nigra are not evidence that all misfolded protein was absent earlier. **Confounders:** One autopsied proband; End-stage neuronal dropout changes visible pathology; Tau/TDP-43 copathology. **Study:** SNCA_G51D_BRITISH_KINDRED_2013. One British G51D kindred; Australian 2026 is an independent kindred but remains replication of the coding-variant causal class. **Access:** full_text_partial; Complete PubMed abstract plus full Materials and methods and Results, including genotype, clinical history, neuronal loss and neuronal/glial pathology, were examined; Discussion and supplements were not fully examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E07 — A novel α-synuclein missense mutation in Parkinson disease. **Source:** [7] · PMID 23427326 · human observational · Weak · supports. **Scope:** SC1. **Decisive perturbation:** no; endogenous: yes. **Examined result:** The original report identified H50Q in one neuropathologically confirmed PD case and nominated it as a new SNCA missense variant. **Inference limit:** A single case does not establish cosegregation or enrichment sufficient for pathogenicity. This report cannot be counted as an established causal SNCA allele in light of Blauwendraat 2018. **Confounders:** Single-case ascertainment; Variant pathogenicity subsequently challenged. **Study:** SNCA_H50Q_INDEX_CASE_2013. Index H50Q case; keep separate from the later population challenge but do not treat their directions as independent positive lines. **Access:** abstract_metadata; Entire short PubMed abstract and identity/status metadata examined. Europe PMC fullTextXML request for PMC3653201 returned HTTP500; body was not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E08 — Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease. **Source:** [8] · PMID 29398121 · human observational · Moderate · supports. **Scope:** SC1. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Primary population/case-control reanalysis of nominated SNCA mutations found H50Q in large population resources and no enrichment in PD, leading the authors to conclude that H50Q is probably not pathogenic. **Inference limit:** The result does not refute well-supported A53T, E46K, G51D or dosage causality. It does constrain using H50Q functional models as genetically validated proof of a disease mechanism. **Confounders:** Population ascertainment and age/penetrance limits; Variant-specific inference. **Study:** SNCA_H50Q_POPULATION_REASSESSMENT_2018. Population reassessment supplies a different failure test than the original single-case nomination; not a separate positive causal line. **Access:** abstract_metadata; Complete PubMed abstract and linked status metadata examined. Europe PMC fullTextXML request for PMC5823280 returned HTTP500; body/supplements were not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E09 — Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease. **Source:** [9] · PMID 29928688 · natural experiment · Strong · supports. **Scope:** SC1. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** A descendant of the Iowa kindred developed parkinsonism at 41, severe cognitive decline and widespread Lewy pathology with severe substantia nigra loss. High-resolution arrays mapped a 1.7 Mb triplication, with 12 genes including SNCA and breakpoints disrupting HERC6 and CCSER1. Comparative mapping included a distinct Lister triplication case. **Inference limit:** This natural copy-gain experiment is not SNCA-only or misfolded-species selective. Its iPSC expression measurements are not a human in-vivo rescue and are not counted here as an additional experimental toxicity study. **Confounders:** Twelve-gene triplication and disrupted flanking genes; Same Iowa familial line as earlier studies. **Study:** SNCA_IOWA_TRIPLICATION_KINDRED. Same Iowa kindred as Miller 2004; Lister mapping is a distinct comparator but does not convert one report into two independent causal modalities. **Access:** full_text_partial; Complete abstract and full Results and Methods were examined, including clinical/autopsy findings, copy-number mapping and expression methods; Discussion and supplements not fully read. Human natural experiment is the counted component. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E10 — SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. **Source:** [10] · PMID 21412942 · natural experiment · Strong · supports. **Scope:** SC1. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** A previously known duplication kindred was characterized with a 4.928 Mb duplicated interval containing 31 genes. SNCA and 13 other genes had increased mRNA in studied cells. Dopamine-transporter imaging was associated with clinical disease severity. **Inference limit:** The interval is not an isolated SNCA perturbation; peripheral/cellular expression and DaTSCAN uptake do not establish toxic misfolded mediation or histological neuron counts. **Confounders:** Large multigene interval; DAT functional imaging rather than neuronal counts. **Study:** SNCA_FRENCH_DUPLICATION_KINDRED_2004. Reported as a previously described duplication kindred. Conservatively grouped with Chartier-Harlin 2004 French family rather than claiming an additional causal family; full family identity not independently resolved. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E11 — Parkin disease: a clinicopathologic entity? **Source:** [11] · PMID 23459986 · human observational · Moderate · supports. **Scope:** SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Five unrelated compound-heterozygous parkin cases were compared with five pathologically confirmed PD cases and four controls, matched first by age at death. Nigral neuronal loss was as severe as in PD, with relatively preserved dorsal tier; sparse Lewy bodies appeared in two of five parkin cases. Cognitive impairment was absent. **Inference limit:** Rare or absent conventional Lewy bodies do not exclude non-inclusion aggregates, transient earlier misfolded species, or alpha-synuclein-mediated toxicity. Genetic parkin disease alone does not refute a mechanism scoped to typical sporadic PD. **Confounders:** Small end-stage autopsy series; Conventional inclusion measurement; Monogenic parkin scope. **Study:** PRKN_DOHERTY_FIVE_CASE_AUTOPSY_2013. Five original unrelated parkin cases, not the narrative commentary 23653422. Pathological observations remain one modality. **Access:** abstract_metadata; Complete structured PubMed abstract and status metadata examined. Europe PMC fullTextXML request for PMC4202385 returned HTTP500; full Methods/Results not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E12 — Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. **Source:** [12] · PMID 19735093 · human observational · Weak · supports. **Scope:** SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** One R1441G LRRK2 patient had onset at 68, an 18-year levodopa-responsive course and mild nigral neuronal loss at autopsy without Lewy bodies/neurites or cytoplasmic alpha-synuclein, tau, LRRK2 or ubiquitin inclusions by the reported examination. **Inference limit:** A conventional inclusion-negative autopsy cannot exclude all misfolded alpha-synuclein species or their earlier presence. One familial LRRK2 case cannot establish the explanation for all sporadic PD. **Confounders:** One end-stage case; Assay sensitivity and time of sampling; Genetic rather than typical sporadic disease. **Study:** LRRK2_R1441G_MARTIMASSO_SINGLE_AUTOPSY_2009. One original R1441G autopsy; do not multiply it with narrative summaries or differently phrased case reports. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E13 — Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. **Source:** [13] · PMID 31235907 · human observational · Weak · supports. **Scope:** SC2, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Correlative light/electron microscopy and tomography in human PD tissue showed alpha-synuclein-positive Lewy pathology crowded with membranes, vesicles and dysmorphic organelles; filaments were observed in many but not all inclusions. Super-resolution microscopy and lipid measurements supported lipid enrichment. **Inference limit:** Morphology does not determine whether inclusions are harmful, protective sequestration, or consequences of organellar damage. It does not establish direct toxic misfolded-species causality. **Confounders:** Postmortem lesion selection; Surviving-neuron sampling; Morphology rather than species-selective perturbation. **Study:** SHAHMORADIAN_LEWY_ULTRASTRUCTURE_2019. One ultrastructural human investigation with orthogonal measurements; multiple imaging resolutions are not multiple causal lines. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E14 — Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. **Source:** [14] · PMID 19286695 · human observational · Moderate · supports. **Scope:** SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** GBA mutations occurred in 33/790 British PD cases and 3/257 controls (OR3.7,95%CI 1.12–12.14). All 17 examined mutation-carrier autopsies had widespread alpha-synuclein pathology (Braak 5–6); cognitive impairment/dementia and hallucinations were frequent clinical features. **Inference limit:** GBA risk and Lewy pathology do not identify alpha-synuclein as the causal mediator of lysosomal risk, or isolate direct neuronal toxicity from inflammation/proteostasis effects. **Confounders:** Rare-variant risk association; Selected carrier autopsies; Possible shared centers/cases with multinational 2009 study. **Study:** GBA_UK_NEUMANN_CLINICAL_AUTOPSY_2009. UK clinical/autopsy study. Overlap with Sidransky 2009 multicenter genetic sample is not resolved; do not treat the two as wholly independent GBA causal lines. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E15 — Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. **Source:** [15] · PMID 19846850 · human observational · Weak · supports. **Scope:** SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** An original 16-center study of 5691 PD cases and 4898 controls found a strong GBA mutation association with PD (OR5.43). Broader sequencing detected mutations missed by testing only the two common alleles, including about 7% of non-Ashkenazi PD cases. **Inference limit:** Case-control genetic risk is not a misfolded-species perturbation or proof of alpha-synuclein mediation. A lysosomal risk allele can affect several disease-relevant pathways. **Confounders:** Population and mutation-screen heterogeneity; Case-control association; Potential overlap with UK2009 report. **Study:** GBA_SIDRANSKY_MULTICENTER_CASECONTROL_2009. One original multinational association study;16 centers do not equal 16 independent mechanisms. Potential UK overlap remains explicitly unresolved. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E16 — Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains. **Source:** [16] · PMID 29917054 · human observational · Weak · supports. **Scope:** SC1, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Blinded SNCA FISH examined 40 sporadic PD brains,5 MSA brains and 25 controls. PD cases had a higher mean fraction of dopaminergic neurons with gains (0.78%vs 0.45%,P=.017); gains were inversely associated with onset age. Authors explicitly allowed either risk-factor or disease-consequence explanations. **Inference limit:** Cross-sectional low-frequency gains are not a causal natural experiment, do not account directly for the much larger neuronal loss, and do not establish a misfolded protein mediator. **Confounders:** Selected relatively young/short-duration cases; Low-frequency FISH measurement; Reverse causation and neuron-survivor bias. **Study:** MOKRETAR_SNCA_SOMATIC_NIGRA_FISH_2018. One original blinded brain FISH investigation; separate probes validate measurement rather than add causal lines. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E17 — Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. **Source:** [17] · PMID 37059509 · human observational · Weak · supports. **Scope:** SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Cross-sectional PPMI analysis included 1123 participants:545 PD,163 controls,54 without dopaminergic deficit,51 prodromal and 310 nonmanifesting carriers. CSF SAA sensitivity for PD was 87.7% and control specificity 96.3%; LRRK2-PD positivity was 67.5% and fell to 34.7% with normal olfaction.44/51 prodromal participants were positive. **Inference limit:** Detection of seeding-competent material is not a direct toxicity assay, a quantitative measure of brain accumulation, or a causal intervention. Positivity before clinical diagnosis supplies risk-marker timing rather than proof that seeds initiated neuronal loss. **Confounders:** Clinical/olfactory/genetic selection; CSF in-vitro amplification rather than neuron survival; Cross-sectional baseline comparison. **Study:** PPMI_CSF_SAA_PROGRAM. PPMI cohort program shared with the 2025 kinetic analysis and the PPMI portion of 2026 LRRK2 analysis; these are overlapping reports, not independent human causal interventions. **Access:** abstract_metadata; Complete structured PubMed abstract and linked status fields examined. PMC10627170 fullTextXML request returned HTTP500; full protocol and supplements were not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E18 — Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases. **Source:** [18] · PMID 40314782 · human observational · Weak · supports. **Scope:** SC2, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** MJF-14 PLA found non-inclusion particulate signal in all six Lewy-negative LRRK2-variant brains, compared with five Lewy-body-disease brains and six controls. Crucially, the six comprise three clinicalPD cases, one neuropathologically confirmedPSP case and two people without clinical neurodegenerative diagnoses. Signals often involved pontocerebellar/inferior-olivary regions. **Inference limit:** These are not six PD cases or six equivalent monogenic pathogenic alleles. Signal abundance does not demonstrate direct neurotoxicity; neuronal loss was not quantified. It does not establish that every Lewy-negative genetic PD has alpha-synuclein-mediated disease. **Confounders:** Only three clinically diagnosedPD in variant group; M1646T/N2081D and combined variants are not uniformly monogenic pathogenic mutations; Small autopsy cohort; PLA amplification/specificity and survivor bias. **Study:** JENSEN_UK_LRRK2_VARIANT_PLA_AUTOPSY_2025. UK Parkinson/Oxford brain-bank cases differ from the Sydney cases in Jensen 2024, but both use the same PLA measurement class; replication is not a new causal modality. **Access:** full_text_partial; Complete abstract, full Materials and methods and Results, and cohort Table 1 examined. Discussion/supplements not fully read; quantitative loss was not performed by authors. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E19 — MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity. **Source:** [19] · PMID 39613827 · human observational · Weak · supports. **Scope:** SC2, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Human component compared anterior cingulate tissue from 10 BraakIV PD,10 BraakVI PD and 10 controls, plus 2 DLB and 2 controls for selected analyses. PLA revealed abundant non-inclusion signal in both PD groups without a significant IV–VI difference. Neuron counts per sampled region did not significantly differ (P=.103); inference of earlier pathology derives from cross-sectional staging. **Inference limit:** PLA signal is not proof that the detected species kills dopamine neurons, or that inclusions protect them. The temporal sequestration interpretation is not direct longitudinal observation. Cell-culture validation is not counted as an additional human primary report here. **Confounders:** Anterior cingulate rather than nigral dopamine neurons; Cross-sectional stages; PLA autofluorescence/control requirements; MJF14 mouse beta-synuclein cross-reactivity documented. **Study:** JENSEN_SYDNEY_HUMAN_PLA_AUTOPSY_2024. Original Sydney human series; different cases from UK2025, shared assay/systematic specificity constraints. **Access:** full_text_partial; Complete abstract plus human tissue/PLA Methods; DLB and PD human Results; and mouse specificity-control Results examined. Other cell-culture/neuronal validation and all supplements not fully read; counted only original human component. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E20 — Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study. **Source:** [20] · PMID 40541208 · human observational · Moderate · supports. **Scope:** SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Longitudinal analysis included 1631 participants across UK, PPMI and Tuebingen cohorts. Faster CSF amplification kinetics predicted cognitive decline (MoCA≤21): PPMIHR2.36(95%CI 1.60–3.46) and TuebingenHR2.17(1.07–4.41). The abstract states this prognostic association for cognition, not every progression endpoint. **Inference limit:** A kinetic prognostic association does not show that selective removal of seeds changes disease, that kinetics quantify brain toxic dose, or that they mediate dopaminergic neuron loss. No SC3 causal dependency follows. **Confounders:** Outcome-specific association; Residual clinical/copathology confounding; Amplification kinetics and brain species differ; PPMI participant reuse. **Study:** PPMI_CSF_SAA_PROGRAM. PPMI component overlaps Siderowf 2023; independent UK/Tuebingen replication supports prognostic confidence, not a new causal perturbation. Study-group ID conservatively marks the shared largest component. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E21 — α-Synuclein Seeding Discriminates Between LRRK2 G2019S Variant Carriers with and Without Parkinson's Disease. **Source:** [21] · PMID 42806694 · human observational · Weak · supports. **Scope:** SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** The Norwegian cohort had 76 LRRK2 carriers,714 idiopathicPD and 411 controls, but CSF SAA measured only 10 LRRK2-PD,30 nonmanifesting carriers,6 controls and 56 idiopathicPD.80% of LRRK2-PD and one unaffected carrier were positive. Exploratory mitochondrial genetic burden association also used a PPMI replication component. **Inference limit:** Full genotyped cohort counts are not SAA sample sizes. Genetic associations with SAA do not establish direct toxicity, misfolded mediation of LRRK2 risk, or a selective survival response. **Confounders:** Very small LRRK2-PD CSF subset; Exploratory genetic burden analyses; PPMI reuse. **Study:** NORWAY_LRRK2_SAA_PLUS_PPMI_PROGRAM_2026. Norwegian assay cohort is a distinct sample; PPMI355 idiopathicPD/118 LRRK2-PD genetic replication reuses the PPMI program and is not independent causal evidence. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E22 — Pathology and Genetics in a Global Cohort of Parkinsonian Disorders. **Source:** [22] · PMID 42258190 · human observational · Weak · supports. **Scope:** SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Original retrospective clinicopathologic/genetic analysis included 3353 eligible donors from 11 brain banks. PD/PDD/DLB clinical diagnoses had 92.0% positive predictive value for Lewy pathology;33/745 neurologically normal controls had Lewy pathology. AD copathology occurred in 426/1064 Lewy-disease cases; GBA1 carriers had more extensive Lewy burden than noncarriers/LRRK2 carriers. **Inference limit:** Pathological prevalence or burden is not direct misfolded-species causality. Incidental Lewy pathology does not prove protection or absence of prodromal disease. Misdiagnosed clinicalPD cases should not be recast as proven alpha-synuclein-independent idiopathicPD. **Confounders:** Retrospective brain-bank selection; Broad Lewy disease classification; Mixed clinical diagnoses and copathology; Likely reuse of historical donor series. **Study:** MDGAP_GP2_MULTIBRAINBANK_AUTOPSY_2026. One pooled original MD-GAP/GP2 analysis;11 brain banks and 3353 reports are not independent causal modalities. Potential donor overlap with earlier brain-bank reports unresolved. **Access:** full_text_partial; Complete abstract plus full Methods and Results examined; Discussion and supplementary eTables not fully read. Related preprint 41929290 identity/status inspected and attached, not separately counted. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E23 — Clinicopathological characterisation of the first Australian family with the p.G51D SNCA mutation. **Source:** [23] · PMID 42660007 · natural experiment · Strong · supports. **Scope:** SC1. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** An Australian G51D kindred showed young-onset parkinsonism and variable expression: proband motor onset 38 and cognitive symptoms 41, sisters onset 51 and 28, and a 27-year-old carrier with subtle thumb tremor. Proband autopsy showed diffuse Lewy pathology. **Inference limit:** Independent kindred replication does not isolate the toxic conformer or supply human selective-aggregation rescue. Variable ages/features preclude an unconditional allele-to-fixed-trajectory prediction. **Confounders:** Small familial series; Age-dependent penetrance; Rare hereditary scope. **Study:** SNCA_G51D_AUSTRALIAN_KINDRED_2026. Distinct Australian rather than British G51D kindred; strengthens coding-variant confidence, not an additional perturbation modality. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E24 — A population scale analysis of rare SNCA variation in the UK Biobank. **Source:** [24] · PMID 33307186 · human observational · Moderate · supports. **Scope:** SC1. **Decisive perturbation:** no; endogenous: yes. **Examined result:** UKBiobank screening of about 500000 people identified 30 SNCA copy-number events (6 duplications,6 deletions,18 complex events), many suspected mosaic. None had diagnosedPD at the reported follow-up; three had some prodromal features without meeting prodromal criteria. Seven of 18 complex events had blood cancer. **Inference limit:** Blood mosaic gains are not established germline brain SNCA duplication and incomplete age/follow-up does not prove inherited dosage harmless. The data constrain indiscriminate penetrance claims, not all familial SNCA causality. **Confounders:** Blood-derived copy-number calls and hematologic mosaicism; Healthy-volunteer/age-follow-up selection; Small number of germline-like duplications. **Study:** UKBIOBANK_RARE_SNCA_COPYVARIANTS_2021. Independent population ascertainment counters disease-family selection; not a direct misfolded-species experiment. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E25 — alpha-Synuclein gene haplotypes are associated with Parkinson's disease. **Source:** [25] · PMID 11532993 · human observational · Weak · supports. **Scope:** SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Original case-control haplotype analysis found common SNCA haplotypes associated with Parkinson disease, extending locus relevance beyond rare Mendelian coding/copy-number families. **Inference limit:** Locus association does not establish a causal allele, valid mediation instrument, toxic conformer, or selective change in dopaminergic survival. It cannot alone cross a causal perturbation threshold. **Confounders:** Linkage disequilibrium; Population/case-control association; No measured toxic species. **Study:** SNCA_COMMON_HAPLOTYPES_CASECONTROL_2001. One original common-haplotype association study; distinct sampling scope from Mendelian families but association remains one nonperturbational class. **Access:** abstract_metadata; Complete PubMed abstract and linked status fields examined; article body and supplements not examined. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E26 — In vivo demonstration that alpha-synuclein oligomers are toxic. **Source:** [26] · PMID 21325059 · animal model · Moderate · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: no. **Examined result:** Oligomer-promoting variants cause greater dopaminergic neuronal loss than fast fibril-forming variants. NeuN comparisons support actual loss; even weaker-promoter expression exceeded familial triplication levels, and unrelated HET-s aggregates were not similarly toxic. **Inference limit:** Mutation changes can alter membrane/function properties as well as assembly; does not identify a universal native sporadic-PD toxic species. **Confounders:** Ectopic variants/expression; Conformer-function confounding; Model exposure; Expression above familial triplication even under weaker promoter. **Study:** Winner2011_21325059. Winner/Masliah/Gage experimental program; variants within one program are linked tests, not independent causal lines. **Access:** full_text_partial; PubMed abstract/status plus selected primary Results/Discussion and design descriptions returned by web search at https://pmc.ncbi.nlm.nih.gov/articles/PMC3053976/ examined: variant controls, NeuN/TH comparison, lower-promoter expression still above familial triplication and HET-s aggregate control. Europe PMC failed500; PMC dataset supplied no XML URL and direct PMC met a browser challenge. Full Methods/supplements not audited. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E27 — Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. **Source:** [27] · PMID 19745811 · animal model · Moderate · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: no. **Examined result:** Prefibrillar variants associate with increased neuronal toxicity and behavioral defects across model systems. **Inference limit:** Biophysical convergence does not separate all normal-function changes; not spontaneous human dopamine-neuron loss. **Confounders:** Engineered sequence; Expression levels; Nonmammalian scope. **Study:** Karpinar2009_19745811. Karpinar/Griesinger experimental series; orthogonal systems share the same engineered-variant assumption. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E28 — Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. **Source:** [28] · PMID 12042811 · in vitro · Weak · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: no. **Examined result:** Dopaminergic apoptosis depends on endogenous dopamine and ROS; soluble alpha-syn/14-3-3 complexes are implicated, whereas cortical neurons show protection. **Inference limit:** Does not establish fibrils or inclusions as the harmful species, ordinary in vivo exposure, or sporadic progression mediation. **Confounders:** Cultured accumulation; Complex composition/conformation unresolved; Neuron-type/state differences. **Study:** Xu2002_12042811. Xu/Yankner human-cell study; distinct platform from rodent PFF and suppression experiments. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E29 — Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. **Source:** [29] · PMID 19409267 · in vitro · Weak · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Snca deletion protects against L-DOPA-induced death without reducing cytosolic dopamine; calcium/dopamine differences confer SN susceptibility. **Inference limit:** Identifies alpha-syn-dependent vulnerability, not a particular misfolded toxic species or an exclusively protein-first process. **Confounders:** Dopamine challenge; Constitutive knockout adaptation; Normal function versus misfolding. **Study:** Mosharov2009_19409267. Mosharov/Sulzer dopamine-homeostasis series; gene-level instrument fails differently from conformer assays. **Access:** full_text_partial; PubMed abstract/status and PMC dataset XML focused Methods/Results examined: native knockout/littermates, astrocyte-supported postnatal cultures, dopamine/calcium perturbation and TH/MAP2 survival counting. No complete-body/supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E30 — Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. **Source:** [30] · PMID 23161999 · animal model · Moderate · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** Seeded pathology progresses with selective SNpc dopamine-neuron loss, reduced dopamine and motor deficits, while adjacent VTA is spared. PBS/monomer and Snca-null recipients lack the same pathology/DA-loss outcome; not all gross/open-field motor outcomes change. **Inference limit:** Does not establish spontaneous sporadic initiation, isolate one conformer or rule out indirect/glial mediators. Main-text loss estimates are TH-defined; complete supplemental stereological details not audited. **Confounders:** Synthetic seed dose/injury; Route versus intracellular toxicity; Selective susceptibility. **Study:** Luk2012_23161999. Luk/Lee Penn PFF program; overlaps investigators/platform with Volpicelli-Daley and Mao material. **Access:** full_text_partial; PubMed abstract/status and PMC dataset XML selected main Results examined: PBS/monomer controls, native Snca-null comparator, time/region pathology versus loss and motor dissociations. Formal methods are in supplements not audited. Partial Results reading, not complete-paper examination. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E31 — Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. **Source:** [31] · PMID 21982369 · in vitro · Weak · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** PFFs recruit native alpha-syn into Lewy-like pathology with synaptic/electrical deficits and later neuronal death. **Inference limit:** Neuron death is not specifically human dopaminergic loss; forced initiation and indirect culture effects remain. **Confounders:** PFF exposure; Non-dopaminergic neuronal scope; Culture maturation. **Study:** Volpicelli-Daley2011_21982369. Volpicelli-Daley/Lee Penn PFF series; linked model assumptions with Luk2012. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E32 — The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. **Source:** [32] · PMID 32075919 · in vitro · Weak · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Inclusion maturation coincides with organelle sequestration, mitochondrial/synaptic disruption and later death beyond early fibrillization. Snca-null cultures do not show PFF-associated death; glial TUNEL precedes later neuronal NeuN/TUNEL death. **Inference limit:** Temporal stages alone do not fully isolate causality; is not proof that every mature inclusion is protective or toxic in human PD. Earlier glial injury leaves non-cell-autonomous contribution possible. **Confounders:** Forced seed; Correlated maturation processes; Primary neuron subtype. **Study:** Mahul-Mellier2020_32075919. Mahul-Mellier/Lashuel inclusion-biogenesis program; distinct structural/omics platform but shares PFF initiation. **Access:** full_text_partial; PubMed abstract/status and Europe PMC XML selected Results examined: stage-specific respiration/organelle assays and KO, glial-versus-neuronal death comparisons. Formal Methods refer to an SI Appendix not examined. No complete-body/supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E33 — Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease. **Source:** [33] · PMID 29487216 · in vitro · Weak · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Incomplete aggregate degradation generates a distinct nonfibrillar fragment associated with mitochondrial damage, energetic stress and mitophagy. **Inference limit:** Cannot infer all injury is direct from localization; selective native conformer depletion and human degeneration mediation are not established in accessed abstract. **Confounders:** Seeded model; Autophagy perturbation pleiotropy; Conformer antibody/processing specificity. **Study:** Grassi2018_29487216. Grassi/Lasmezas mitochondrial-conformer program; clearance failure can generate toxic species rather than exclude direct toxicity. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E34 — Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. **Source:** [34] · PMID 12376616 · animal model · Strong · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** Knockout resists dopamine-neuron degeneration; resistance tracks inability of MPTP to inhibit complex I rather than abnormal dopamine-transporter function. **Inference limit:** Deletion changes normal protein biology and toxin response; no isolated misfolded-species removal. **Confounders:** Developmental adaptation; Toxin metabolism/action; Normal function instrument. **Study:** Dauer2002_12376616. Dauer/Sulzer genetic-toxin study; shared investigators with Mosharov but different in vivo toxin mechanism. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E35 — Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity. **Source:** [35] · PMID 29497361 · animal model · Moderate · contradicts. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Suppression precedes MHC-I induction, microglial/T-cell recruitment and later nigrostriatal neuronal loss; control hairpin/cerebellar exposure does not reproduce injury. **Inference limit:** Does not prove every suppression strategy is unsafe or exclude shRNA/dose effects; no exclusive misfolded gain-of-function instrument. **Confounders:** RNAi expression/dose; Vector/hairpin toxicity; Inflammatory mediation. **Study:** Benskey2018_29497361. Benskey/Manfredsson suppression program; mechanistic extension of loss-of-function toxicity, not independent replication of every RNAi method. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E36 — shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. **Source:** [36] · PMID 26075822 · animal model · Strong · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** Partial knockdown is tolerated at baseline and protects rotenone-exposed nigral neurons/terminals while attenuating motor deficits. Blinded counts co-label TH, MAP2 and nuclei; functional/neuritic protection accompanies counts. **Inference limit:** Total protein reduction changes normal function and aggregation substrate simultaneously; does not selectively identify a misfolded toxic species. Count inclusion requires TH positivity, so it is not an independent Nissl-only rescue measure. **Confounders:** Total-protein manipulation; Rotenone context; RNAi specificity/degree. **Study:** Zharikov2015_26075822. Zharikov/Greenamyre adult RNAi program; distinct toxin line, correlated vector assumptions with its long-term follow-up. **Access:** full_text_partial; PubMed abstract/status and selected primary Methods/Results returned by web search at https://pmc.ncbi.nlm.nih.gov/articles/PMC4563670/ examined: paired-vector lesion comparisons and blinded stereology of co-labeled MAP2/TH/nuclei. Europe PMC failed500 and PMC dataset supplied no XML URL. No full-body/supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E37 — Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration. **Source:** [37] · PMID 30658149 · animal model · Moderate · null. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Strong long-term knockdown shows no Nissl-defined neuron loss or significant motor dysfunction; TH declines with both vectors. **Inference limit:** Tolerance in this delivery context does not prove universal safety or disease rescue. TH-positive count alone can conflate phenotype suppression with death. **Confounders:** Vector/hairpin effects; Degree/time of depletion; Unchallenged context. **Study:** Zharikov2019_30658149. Zharikov/Greenamyre RNAi program; separate age/duration experiment from 2015, shared delivery/lab failure modes. **Access:** full_text_partial; PubMed abstract/status and PMC dataset XML focused Methods/Results examined: vector specificity/batches, Nissl/DAPI versus TH counting and long-term clinical/molecular outcomes. Figure1 comparison inset reuses 2015 data; new cohort measured here. No complete-body/supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E38 — α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. **Source:** [38] · PMID 33682798 · animal model · Moderate · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** ASOs reduce pathology and preserve TH-positive counts; some pretreatment paradigms normalize dopamine. Transient post-seed treatment later preserves TH despite increased aggregate counts. **Inference limit:** Examined survival estimates are TH-based, without separate pan-neuronal counts; total-protein lowering is not misfolded-specific. Behavioral improvement is a trend in the accessed mouse paradigm. **Confounders:** TH phenotype versus survival; Total substrate reduction; PFF initiation; Species/paradigm differences. **Study:** Cole2021_33682798. Cole/Ionis/Greenamyre ASO program; multiple paradigms are one linked therapeutic program, not independent human causal lines. **Access:** full_text_partial; Focused Europe PMC XML Methods/Results read: transient/sustained and pre/post-PFF ASOs, TH stereology, dopamine assays and PFF/animal dosing. No complete-body/supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E39 — Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. **Source:** [39] · PMID 27708076 · animal model · Moderate · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** Lag3 loss delays PFF-associated dopaminergic loss and biochemical/behavioral deficits. In vivo TH/Nissl stereology and dopamine/motor outcomes improve; cultured KO-to-re-expression rescue, PI/NeuN and calcium assays strengthen a model-specific uptake-to-injury dependency. **Inference limit:** Route dependence does not establish a mandatory extracellular mechanism for all PD or isolate intrinsic conformer toxicity; receptor expression/specificity is contested. Global Lag3 deletion also affects T-cell homeostasis; it is not a neuronal-specific knockout. **Confounders:** LAG3 expression/assay dispute; Immune receptor effects; PFF context; Global receptor deletion/altered T-cell homeostasis. **Study:** Mao2016_27708076. Mao/Dawson LAG3 program; one receptor program with linked molecular and outcome assays. **Access:** full_text_partial; PubMed abstract/status and PMC dataset XML focused Methods/Results examined: native receptor KO, neuronal rescue/PI/NeuN/calcium, PFF/monomer/PBS injections, TH/Nissl in vivo survival and motor outcomes; mouse strain has altered T-cell homeostasis. No full supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E40 — LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies. **Source:** [40] · PMID 34309222 · animal model · Moderate · null. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** No neuronal expression detected; inducible LAG3 does not increase human-culture seeding, knockout does not change A53T survival or slice pathology. **Inference limit:** Different model/region from Mao nigrostriatal PFF experiment; not a direct refutation of all alpha-syn toxicity or all uptake routes. **Confounders:** Detection limits; A53T motor/survival versus dopamine-neuron loss; Culture/slice route differences. **Study:** Emmenegger2021_34309222. Emmenegger/Aguzzi/Jucker/Polymenidou independent receptor-specificity program; some transcript datasets reused, alpha-specific intervention sections newly read for this review. **Access:** full_text_partial; New alpha-specific Europe PMC XML Methods/Results read: human-culture induction/seeding, A53T survival, PFF slices and animal/culture protocols. Expression sections were previously examined for tau; alpha intervention claims newly examined here. No complete supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E41 — Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. **Source:** [41] · PMID 31165254 · animal model · Moderate · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** yes in its stated scope; endogenous: no. **Examined result:** Aggregation-profile modulation restores dopamine release and preserves TH counts/gait; baseline nigral degeneration is NeuN-confirmed. Dense clusters/HMW signal decrease while dispersed small species increase. **Inference limit:** Treatment rescue counts examined are TH-based; off-target aggregation-modulator effects and artificial substrate remain. Small species are not automatically the harmful oligomers of another assay. **Confounders:** Truncated transgene/native-null background; Drug specificity; TH treatment endpoint; Species identity across assays. **Study:** Wegrzynowicz2019_31165254. Wegrzynowicz/Spillantini/Giese MI2 program; imaging, pathology and drug rescue are linked program components. **Access:** full_text_partial; Focused Europe PMC XML Methods/Results read: model construction/null background, randomization/blinding, TH/NeuN baseline counting, anle138b timing, aggregate-profile and dopamine/TH outcomes. Selected reading; no complete-body/supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E42 — Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. **Source:** [42] · PMID 30472757 · in vitro · Weak · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Reduced/absent SNCA alleles resist pS129 Lewy-like pathology. **Inference limit:** Accessed abstract does not show neuron-loss rescue; a seeding-resistant graft candidate is not established protection in human PD. **Confounders:** Pathology-only endpoint; Developmental editing; PFF challenge. **Study:** Chen2019_30472757. Chen/Morgan stem-cell editing program; native human gene instrument tests substrate requirement but not clinical progression. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E43 — Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons. **Source:** [43] · PMID 34155194 · in vitro · Weak · supports. **Scope:** SC1, SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Brain-amplified strains produce dose/strain-dependent death in triplication neurons, reversed by isogenic dosage normalization. Similar early seeding does not imply equal later toxicity. **Inference limit:** Does not establish identical toxicity in normal-dose sporadic neurons; amplification may select conformers and gene-dose rescue is not misfolded-selective depletion. **Confounders:** Familial dosage; PMCA conformer selection; In vitro exposure; Shared maturation susceptibility. **Study:** Tanudjojo2021_34155194. Tanudjojo/Ryten/Kunath/Melki human-strain program; three clones from one triplication background are not three independent patients; isogenic lines originate in prior work. **Access:** full_text_partial; Focused Europe PMC XML Methods/Results read: brain amplification/controls, neuron differentiation, seed exposure, triplication/healthy-control comparison and isogenic SNCA correction. No complete-body/supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E44 — Differential pathological dynamics triggered by distinct Parkinson patient-derived α-synuclein extracts in nonhuman primates. **Source:** [44] · PMID 40531987 · animal model · Moderate · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: no. **Examined result:** Equal-total-alpha-syn LA/SA patient fractions yield different time courses and similar later TH-defined nigrostriatal deficits. SA contains small amyloid assemblies, so its former noLB label does not mean no pathological alpha-syn. **Inference limit:** Not spontaneous human causality or alpha-syn-specific fraction toxicity: extract cofactors, sonication, untreated rather than matched extract controls and partial endpoint audit remain. Prior 24-month findings are reused. **Confounders:** Extract cofactors; Forced delivery; Small primate cohorts; Report/cohort overlap; Reuse of previously reported24-month observations; SA/noLB contains small aggregates; No alpha-syn immunodepletion rescue in accessed design. **Study:** Kinet2025_40531987. Bezard/Dehay patient-fraction primate program; explicitly reuses fraction characterization and 24-month observations from Bourdenx 2020 PMID 32426502/DOI 10.1126/sciadv.aaz9165. Earlier 6/12-month/proteomic analysis extends that program rather than constituting an independent replication. **Access:** full_text_partial; Focused Europe PMC XML Methods/Results read: fraction purification/characterization provenance, cohort allocation/injections, TH/Nissl methods and time-course degeneration. Earlier fraction characterization and 24-month observations explicitly reuse2020 report 32426502; supplements not comprehensively audited. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E45 — Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons. **Source:** [45] · PMID 40541955 · in vitro · Weak · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Parkin deficiency increases native aggregated/released/seeding-competent alpha-syn and synaptic/Ca2+ abnormalities, including dopamine-neuronal and astrocytic aggregates. **Inference limit:** No alpha-syn-selective rescue establishes mediation or direct neuron death; PARK2 changes clearance/organellar biology upstream. Lewy-body absence cannot be equated with absence of soluble/pathological alpha-syn. **Confounders:** Parkin pleiotropy; Mixed neuronal/glial cells; Synaptic rather than cell-loss endpoint. **Study:** Schmidt2025_40541955. 2025 PARK2 isogenic culture program; clones/differentiations test one upstream genetic context, not population generalization. **Access:** full_text_partial; Focused Europe PMC XML Methods/Results read: culture composition, native aggregates/seeding, synapse/calcium outcomes, differentiation and PARK2/SNCA CRISPRi assay design. No complete-body/supplement audit. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E46 — Selective neurodegeneration generated by intravenous α-synuclein pre-formed fibril administration is not associated with endogenous α-synuclein levels in the rat brain. **Source:** [46] · PMID 36321260 · animal model · Moderate · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Specific midbrain dopamine and other neuronal populations are lost, without association to region-level native alpha-syn expression. **Inference limit:** Regional expression is not single-cell exposure or genetic deletion; result does not prove alpha-syn-independent degeneration or ordinary spontaneous delivery. **Confounders:** RVG9R carrier/dose; Region-level abundance; No selective native conformer suppression. **Study:** Kuan2023_36321260. Independent systemic-delivery rat program; route/dose assumptions differ from intracerebral PFF studies. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E47 — Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers. **Source:** [47] · PMID 29242346 · in vitro · Weak · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: no. **Examined result:** Lipophilic membrane interaction and bilayer insertion define toxic oligomer properties; targeted mutation reduces cellular toxicity. **Inference limit:** Membrane/toxicity mechanism is plausible but exposure, normal-function effects and human dopamine-cell specificity are unproven. **Confounders:** Artificial oligomer preparation; Sequence-function confounding; Non-dopaminergic assay. **Study:** Fusco2017_29242346. Fusco/Vendruscolo/Dobson structural program; orthogonal physical mechanism but shared recombinant preparation failure mode. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E48 — The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells. **Source:** [48] · PMID 33753734 · in vitro · Weak · supports. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: no. **Examined result:** Fibrils release toxic soluble oligomers; shorter fibrils cause greater immediate dysfunction consistent with more ends. **Inference limit:** Aggregate categories are kinetically interconverting; direct human dopamine-neuron loss or ordinary concentration is not established. **Confounders:** Artificial concentration/assembly; Cellular dysfunction versus in vivo survival; Released species identification. **Study:** Cascella2021_33753734. Cascella/Cecchi recombinant species-release program; distinct kinetics assay with shared artificial-assembly assumptions. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E49 — In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. **Source:** [49] · PMID 20551914 · animal model · Strong · contradicts. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** yes in its stated scope; endogenous: yes. **Examined result:** Suppression produces marker-confirmed cell loss, striatal dopamine depletion and behavioral asymmetry; protein re-expression partially reverses injury. **Inference limit:** Does not show misfolded accumulation removal is harmful, or invalidate all reduction therapies; vector/hairpin specificity, suppression level and rescue dose matter. **Confounders:** RNAi/vector context; Normal protein depletion; Ectopic rescue. **Study:** Gorbatyuk2010_20551914. Gorbatyuk suppression/rescue program; native-function causal counterpoint, with delivery failure modes shared by other AAV RNAi studies. **Access:** full_text_partial; PubMed abstract/status plus selected primary Results/Discussion and design descriptions returned by web search at https://pmc.ncbi.nlm.nih.gov/articles/PMC2927065/ examined: two hairpins, three irrelevant controls, dose/efficacy and AADC/VMAT/GFP checks. Animal Methods/supplements not comprehensively audited; Europe PMC failed500 and PMC dataset supplied no XML URL. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E50 — In Vitro Protective Action of Monomeric and Fibrillar α-Synuclein on Neuronal Cells Exposed to the Dopaminergic Toxins Salsolinol and DOPAL. **Source:** [50] · PMID 33080132 · in vitro · Weak · contradicts. **Scope:** SC2, SC3, SC4. **Decisive perturbation:** no; endogenous: no. **Examined result:** Monomer protects against both catechols; fibrils improve DOPAL but not salsolinol viability, with potentially less-toxic DOPAL adduct formation. **Inference limit:** Not proof Lewy-body sequestration protects in human PD; response depends on toxin and assembly and may reflect chemical trapping rather than native intracellular storage. **Confounders:** Artificial protein/toxin exposure; Catechol chemistry; Culture-specific protection. **Study:** Carmo-Gonçalves2020_33080132. Independent catechol-protection primary culture assay; tests a different failure mode from pathological seeding. **Access:** abstract_metadata; PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E51 — Trial of Prasinezumab in Early-Stage Parkinson's Disease. **Source:** [51] · PMID 35921451 · human interventional · Moderate · null. **Scope:** SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** PASADENA randomized 316 early PD participants; neither prasinezumab dose met the global MDS-UPDRS primary endpoint, and dopamine-transporter imaging did not differ substantially from placebo. **Inference limit:** Does not show disease modification or neuron survival; it tests extracellular antibody treatment after clinical diagnosis rather than selective removal of intracellular toxic conformers. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT03100149. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** abstract_metadata; Primary PubMed abstract and metadata read. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E52 — Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. **Source:** [52] · PMID 38622249 · human interventional · Moderate · supports. **Scope:** SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Exploratory analyses of PASADENA baseline-defined subpopulations found a larger numerical motor-sign effect in groups expected to progress faster. **Inference limit:** These secondary analyses follow a failed primary endpoint; subgroup definitions were prespecified, but the effect interpretation remains exploratory and requires independent randomized confirmation. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT03100149. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** full_text_partial; Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E53 — Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. **Source:** [53] · PMID 39379705 · human interventional · Moderate · supports. **Scope:** SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** PASADENA open-label extension participants had slower motor-score deterioration than a weighted external PPMI comparator over four years. **Inference limit:** No concurrent placebo beyond the first year; selection, residual confounding, medication differences, examiner/placebo effects and cohort mismatch can explain some or all of the contrast; no direct neuronal survival or misfolded-species mediation. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT03100149. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** full_text_partial; Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E54 — Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study. **Source:** [54] · PMID 42208564 · human interventional · Moderate · null. **Scope:** SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** PADOVA randomized 586 early PD participants on stable symptomatic medication; the primary motor-event endpoint was not met (HR 0.84, 95% CI 0.69–1.01; p=0.066), with prespecified exploratory signals favoring further study. **Inference limit:** A suggestive effect is not a positive primary trial or proof of neuroprotection/direct toxicity; the July 2026 erratum corrects the appendix but its detailed impact is unresolved because the corrected appendix was not examined. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT04777331. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** abstract_metadata; Primary PubMed abstract and metadata read. **Opened/status checked:** 2026-10-03. **Status:** erratum: PMID 42392102; DOI 10.1016/S0140-6736(26)01301-2; appendix corrected as of 2026-07-02; correction body read; corrected appendix not examined, detailed scientific impact unresolved.. ### E55 — Trial of Cinpanemab in Early Parkinson's Disease. **Source:** [55] · PMID 35921450 · human interventional · Moderate · null. **Scope:** SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** SPARK randomized 357 early PD participants; no cinpanemab dose improved clinical progression or DaT-SPECT versus placebo, and the trial was stopped for lack of efficacy. **Inference limit:** No inference that every intracellular misfolded species was effectively neutralized; failure of this extracellular antibody does not establish lack of any alpha-synuclein contribution. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT03318523. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** abstract_metadata; Primary PubMed abstract and metadata read. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E56 — Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. **Source:** [56] · PMID 38315945 · human interventional · Moderate · null. **Scope:** SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** SPARK biomarker analyses confirmed seeds in most of the baseline CSF subgroup, but neither clinical nor imaging/fluid biomarkers showed a cinpanemab treatment effect. **Inference limit:** Baseline seeding positivity is disease classification, not toxic-species dependence or direct neuron killing; no substantial reduction of the measured seed signal was demonstrated. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT03318523. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** abstract_metadata; Primary PubMed abstract and metadata read. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E57 — Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial. **Source:** [57] · PMID 38902546 · human interventional · Moderate · supports. **Scope:** SC3, SC4. **Decisive perturbation:** no; endogenous: yes. **Examined result:** UB-312 phase 1 PD vaccination induced antibodies in serum and a subset of CSF samples; exploratory seed-amplification maximum fluorescence fell in one active dose group. Randomized groups did not differ statistically on clinical scales. **Inference limit:** The small safety/immunogenicity trial does not establish clinical benefit or neuronal preservation. Post-treatment antibody-positive subgroup contrasts are nonrandomized, and antibody effects on the amplification assay require separation from depletion of brain toxic species. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT04075318. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** full_text_partial; Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E58 — Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. **Source:** [58] · PMID 32562684 · human interventional · Moderate · supports. **Scope:** SC3. **Decisive perturbation:** no; endogenous: yes. **Examined result:** PD01A dose-randomized phase 1 PD immunization and extensions showed a humoral response that could be reactivated with booster dosing and acceptable tolerability over follow-up. **Inference limit:** Dose comparison without a placebo efficacy contrast cannot demonstrate slowed degeneration; immunogenicity and inferred engagement do not isolate the proposed toxic mediator. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** PD01A-program:EudraCT2011-002650-31/2013-001774-20/2014-002489-54/2015-004854-16. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** abstract_metadata; Primary PubMed abstract and metadata read. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E59 — Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. **Source:** [59] · PMID 34092654 · human interventional · Moderate · supports. **Scope:** SC3. **Decisive perturbation:** no; endogenous: yes. **Examined result:** PD03A placebo-controlled phase 1 PD vaccination generated anti-peptide and alpha-synuclein-specific antibodies with acceptable tolerability. **Inference limit:** The safety study was not powered for clinical efficacy; no significant clinical-scale or striatal DAT-SPECT contrast, and symptomatic medication changes limit interpretation of clinical trends. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** PD03A-EudraCT2014-000568-16. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** full_text_partial; Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E60 — Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422. **Source:** [60] · PMID 38494847 · human interventional · Moderate · supports. **Scope:** SC3. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Single-dose Lu AF82422 reduced plasma free alpha-synuclein and the CSF free-to-total ratio in the high-dose PD cohort, supporting central compartment engagement. **Inference limit:** Free/total ratio modulation does not demonstrate removal of neuron-intrinsic misfolded species, neuronal survival, or a clinical trajectory effect. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT03611569. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** abstract_metadata; Primary PubMed abstract and metadata read. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E61 — Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50. **Source:** [61] · PMID 40936651 · human interventional · Moderate · supports. **Scope:** SC3. **Decisive perturbation:** no; endogenous: yes. **Examined result:** MEDI1341 randomized phase 1 healthy and PD studies measured dose-dependent lowering of CSF free alpha-synuclein; the highest PD dose reduced the median CSF-free signal by 59.0% at Day85. **Inference limit:** Target binding/sequestration lowers the free assay signal; it does not establish reduction of total pathogenic tissue burden or clinical disease modification. Read Methods/Results show no notable clinical treatment-group trends. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT03272165+NCT04449484. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** full_text_partial; Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E62 — Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. **Source:** [62] · PMID 39892989 · human interventional · Moderate · supports. **Scope:** SC3. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Crosslink-stabilized assays of cinpanemab phase 1 samples directly detected dose- and time-dependent drug–alpha-synuclein complexes in human CSF. **Inference limit:** This corrects an absolute claim that CNS engagement was never measured, but does not demonstrate intracellular aggregate depletion or efficacy in the separate SPARK trial. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT02459886. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** abstract_metadata; Primary PubMed abstract and metadata read. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E63 — First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. **Source:** [63] · PMID 27886407 · human interventional · Moderate · supports. **Scope:** SC3. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Single-dose PRX002 in healthy participants produced dose-dependent reductions of free serum alpha-synuclein with favorable phase 1 tolerability. **Inference limit:** Peripheral serum binding in healthy participants gives no neuronal-survival or PD progression evidence; total signal increased after binding. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT02095171. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** abstract_metadata; Primary PubMed abstract and metadata read. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E64 — Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. **Source:** [64] · PMID 31211448 · human interventional · Moderate · supports. **Scope:** SC3. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Cinpanemab phase 1 healthy/PD study measured dose-proportional exposure and plasma complexes; CSF drug levels were a small fraction of serum levels. **Inference limit:** The original phase 1 assay could not measure CSF complexes; this was subsequently resolved by the 2025 assay report from the same study, rather than representing two independent clinical experiments. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT02459886. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** full_text_partial; Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited. **Opened/status checked:** 2026-10-03. **Status:** none_found. ### E65 — Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. **Source:** [65] · PMID 29913017 · human interventional · Moderate · supports. **Scope:** SC3. **Decisive perturbation:** no; endogenous: yes. **Examined result:** Multiple-dose PRX002 in PD reduced free serum alpha-synuclein and produced dose-dependent CSF drug exposure with generally favorable phase 1 tolerability. **Inference limit:** CSF exposure was predicted to engage extracellular aggregates, rather than demonstrating their selective clearance or neuronal preservation. **Confounders:** Clinical symptoms do not directly count surviving dopaminergic neurons; Extracellular/free-CSF target does not establish intracellular toxic-species depletion; Small safety cohorts or endpoint/subgroup/external comparator limits as described. **Study:** NCT02157714. Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained. **Access:** abstract_metadata; Primary PubMed abstract and metadata read. **Opened/status checked:** 2026-10-03. **Status:** none_found. ## ADVERSARIAL REVIEW AND APPROVAL **Authoring model:** Sol 6.1. **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-06. **Scope of checks.** PMIDs verified 65/65 against PubMed (`esummary`/`efetch`): title, first author, year, journal and DOI matched for every reference; 0 unresolvable, 0 wrong-record substitutions. Retraction / expression-of-concern screen run on all 65 records via linked `CommentsCorrections`: none found. One erratum is linked (PMID 42392102, to PADOVA [54]); it was already recorded in the citation ledger and its unresolved-appendix limitation is already stated in the review. 12 load-bearing claims spot-checked against primary abstracts or full text. Scoring logic re-derived against `framework/hsef-hypothesis-review-v5/SKILL.md`, `references/hsef-framework.md` and `references/evidence-rubrics/01-neurodegeneration.md`. Internal consistency checked across review.md, scorecard.json and the batch README. **Findings.** No correction was required. No citation, attribution, arithmetic, scoring-logic or internal-consistency error was identified. | ID | Severity | Location | Original → corrected | Evidence | |---|---|---|---|---| | — | — | — | No corrections applied | — | **Verified load-bearing claims (sample).** PADOVA n=586 randomized, primary endpoint not met, HR 0.84 (95% CI 0.69–1.01), p=0.066 — matches the primary report verbatim. MEDI1341 −59.0% median CSF free α-synuclein at Day 85 in the 2000 mg PD group — matches. Jensen 2025 LRRK2 cohort composition (three clinical PD, one neuropathologically confirmed PSP, two without clinical neurodegenerative diagnoses among six Lewy-body-negative cases) — matches the Results text; the review's refusal to read these as six comparable PD cases is correct. Zharikov 2019 (no Nissl-defined nigral loss at 12 months despite TH decline with both vectors) — matches. Dauer 2002, Zharikov 2015, Gorbatyuk 2010, Cole 2021, Mao 2016, Soscia-independent items, PASADENA and SPARK primary outcomes — all consistent with their sources. PARAISO NCT07174310 confirmed recruiting phase 3 with estimated primary completion 2029-06-30. **Scoring logic — checked and upheld.** The declared `scope-matched` rule is applied as written: the overall letter is taken from SC4, the only subclaim whose scope matches the central typical-human-sporadic-PD claim, not from the highest subclaim (SC1 Ζ). This is the specific error the framework warns about and it was not made. Hard caps are applied per subclaim before thresholds; the Β/Γ/Δ boundary check quotes the rubric verbatim and the quotations are accurate. Reported aggregation alternatives (weakest-link Γ, primary-subclaim SC3 Γ) are arithmetically correct. Causal tally (16 flagged, 15 retained after excluding the MI2 artificial-substrate item) is internally consistent. **Rejected findings (checked, no change).** 1. *SC1 at Ζ rather than Ε.* Ζ requires "multiple independent causal lines in vivo", "replication across at least two relevant systems" and "narrowing of major alternative models". A reviewer could argue that segregating coding variants and wild-type locus multiplications are one evidence class (human genetics) rather than two systems. The framework does not force a reduction: universal cap 6 expressly permits the familial case to "reach Δ or higher on its own terms", SC1's declared scope *is* familial SNCA-linked disease (so Ε's failed-generalization trigger does not bite within that scope), and the two designs exclude different assignment errors. Judgement call left as written. It is also non-gating: under scope-matched aggregation the overall letter is unaffected. 2. *Role of mechanism `epiphenomenon` rather than `reinforcing / stabilizing factor`.* The framework's derivation stops at the first match, and step 2 asks whether a causal dependency is demonstrated in either direction at the scored scope. At the full sporadic-human scope it is not. The review already flags the label as operational and explicitly denies that it means biological inertness. Defensible as written. 3. *Reviewer/metadata string.* `scorecard.json` records `reviewer`/`generated_by` as "Codex"; the batch attributes authorship to Sol 6.1. This is a harness-identifier question rather than a demonstrable factual error in the review, so the field was left unchanged and is noted here for the lead. 4. *Mao 2016 Nissl detail.* The review's statement that LAG3 deletion preserved Nissl-positive as well as TH-positive neurons rests on the paper's figures rather than its abstract; the abstract ("substantially delayed α-syn PFF-induced loss of dopamine neurons… and behavioral deficits") is consistent and does not contradict it. No change. **Residual limitations.** Verification of claims drawn from figure panels and supplements (e.g. the Mao Nissl counts, the Cole ASO dopamine comparison) rests on the authoring review's own full-text reading; this adversarial pass confirmed abstracts, open-access full text where available, registry records and all reference metadata, not every figure. The corrected PADOVA appendix remains unexamined, as the review itself states. **Approval:** Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-06. ## References 1. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (New York, N.Y.). 1997. doi:10.1126/science.276.5321.2045 [PubMed](https://pubmed.ncbi.nlm.nih.gov/9197268/) 2. Zarranz JJ, Alegre J, Gómez-Esteban JC et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of neurology. 2004. doi:10.1002/ana.10795 [PubMed](https://pubmed.ncbi.nlm.nih.gov/14755719/) 3. Chartier-Harlin MC, Kachergus J, Roumier C et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (London, England). 2004. doi:10.1016/S0140-6736(04)17103-1 [PubMed](https://pubmed.ncbi.nlm.nih.gov/15451224/) 4. Ibáñez P, Bonnet AM, Débarges B et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (London, England). 2004. doi:10.1016/S0140-6736(04)17104-3 [PubMed](https://pubmed.ncbi.nlm.nih.gov/15451225/) 5. Miller DW, Hague SM, Clarimon J et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology. 2004. doi:10.1212/01.wnl.0000127517.33208.f4 [PubMed](https://pubmed.ncbi.nlm.nih.gov/15159488/) 6. Kiely AP, Asi YT, Kara E et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta neuropathologica. 2013. doi:10.1007/s00401-013-1096-7 [PubMed](https://pubmed.ncbi.nlm.nih.gov/23404372/) 7. Proukakis C, Dudzik CG, Brier T et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology. 2013. doi:10.1212/WNL.0b013e31828727ba [PubMed](https://pubmed.ncbi.nlm.nih.gov/23427326/) 8. Blauwendraat C, Kia DA, Pihlstrøm L et al. Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease. Neurobiology of aging. 2018. doi:10.1016/j.neurobiolaging.2017.12.012 [PubMed](https://pubmed.ncbi.nlm.nih.gov/29398121/) 9. Zafar F, Valappil RA, Kim S et al. Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease. NPJ Parkinson's disease. 2018. doi:10.1038/s41531-018-0054-4 [PubMed](https://pubmed.ncbi.nlm.nih.gov/29928688/) 10. Mutez E, Leprêtre F, Le Rhun E et al. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Human mutation. 2011. doi:10.1002/humu.21459 [PubMed](https://pubmed.ncbi.nlm.nih.gov/21412942/) 11. Doherty KM, Silveira-Moriyama L, Parkkinen L et al. Parkin disease: a clinicopathologic entity? JAMA neurology. 2013. doi:10.1001/jamaneurol.2013.172 [PubMed](https://pubmed.ncbi.nlm.nih.gov/23459986/) 12. Martí-Massó JF, Ruiz-Martínez J, Bolaño MJ et al. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Movement disorders : official journal of the Movement Disorder Society. 2009. doi:10.1002/mds.22677 [PubMed](https://pubmed.ncbi.nlm.nih.gov/19735093/) 13. Shahmoradian SH, Lewis AJ, Genoud C et al. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nature neuroscience. 2019. doi:10.1038/s41593-019-0423-2 [PubMed](https://pubmed.ncbi.nlm.nih.gov/31235907/) 14. Neumann J, Bras J, Deas E et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain : a journal of neurology. 2009. doi:10.1093/brain/awp044 [PubMed](https://pubmed.ncbi.nlm.nih.gov/19286695/) 15. Sidransky E, Nalls MA, Aasly JO et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England journal of medicine. 2009. doi:10.1056/NEJMoa0901281 [PubMed](https://pubmed.ncbi.nlm.nih.gov/19846850/) 16. Mokretar K, Pease D, Taanman JW et al. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains. Brain : a journal of neurology. 2018. doi:10.1093/brain/awy157 [PubMed](https://pubmed.ncbi.nlm.nih.gov/29917054/) 17. Siderowf A, Concha-Marambio L, Lafontant DE et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. The Lancet. Neurology. 2023. doi:10.1016/S1474-4422(23)00109-6 [PubMed](https://pubmed.ncbi.nlm.nih.gov/37059509/) 18. Jensen NM, Vitic Z, Antorini MR et al. Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases. Acta neuropathologica. 2025. doi:10.1007/s00401-025-02871-w [PubMed](https://pubmed.ncbi.nlm.nih.gov/40314782/) 19. Jensen NM, Fu Y, Betzer C et al. MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity. NPJ Parkinson's disease. 2024. doi:10.1038/s41531-024-00841-9 [PubMed](https://pubmed.ncbi.nlm.nih.gov/39613827/) 20. Orrú CD, Vaughan DP, Vijiaratnam N et al. Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study. The Lancet. Neurology. 2025. doi:10.1016/S1474-4422(25)00157-7 [PubMed](https://pubmed.ncbi.nlm.nih.gov/40541208/) 21. Lüth T, Gabbert C, Kleinz T et al. α-Synuclein Seeding Discriminates Between LRRK2 G2019S Variant Carriers with and Without Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2026. doi:10.1002/mds.70553 [PubMed](https://pubmed.ncbi.nlm.nih.gov/42806694/) 22. Wu LY, du Toit T, Georgiades T et al. Pathology and Genetics in a Global Cohort of Parkinsonian Disorders. JAMA neurology. 2026. doi:10.1001/jamaneurol.2026.1634 [PubMed](https://pubmed.ncbi.nlm.nih.gov/42258190/) 23. Panegyres PK, Kwok JB, Junckerstorff R. Clinicopathological characterisation of the first Australian family with the p.G51D SNCA mutation. Parkinsonism & related disorders. 2026. doi:10.1016/j.parkreldis.2026.108955 [PubMed](https://pubmed.ncbi.nlm.nih.gov/42660007/) 24. Blauwendraat C, Makarious MB, Leonard HL et al. A population scale analysis of rare SNCA variation in the UK Biobank. Neurobiology of disease. 2021. doi:10.1016/j.nbd.2020.105182 [PubMed](https://pubmed.ncbi.nlm.nih.gov/33307186/) 25. Farrer M, Maraganore DM, Lockhart P et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Human molecular genetics. 2001. doi:10.1093/hmg/10.17.1847 [PubMed](https://pubmed.ncbi.nlm.nih.gov/11532993/) 26. Winner B et al. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.1100976108. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21325059/) 27. Karpinar DP et al. (2009). Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. The EMBO journal. DOI: 10.1038/emboj.2009.257. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19745811/) 28. Xu J et al. (2002). Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nature medicine. DOI: 10.1038/nm0602-600. [PubMed](https://pubmed.ncbi.nlm.nih.gov/12042811/) 29. Mosharov EV et al. (2009). Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron. DOI: 10.1016/j.neuron.2009.01.033. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19409267/) 30. Luk KC et al. (2012). Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (New York, N.Y.). DOI: 10.1126/science.1227157. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23161999/) 31. Volpicelli-Daley LA et al. (2011). Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. DOI: 10.1016/j.neuron.2011.08.033. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21982369/) 32. Mahul-Mellier AL et al. (2020). The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.1913904117. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32075919/) 33. Grassi D et al. (2018). Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.1713849115. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29487216/) 34. Dauer W et al. (2002). Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.172514599. [PubMed](https://pubmed.ncbi.nlm.nih.gov/12376616/) 35. Benskey MJ et al. (2018). Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity. Frontiers in molecular neuroscience. DOI: 10.3389/fnmol.2018.00036. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29497361/) 36. Zharikov AD et al. (2015). shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. The Journal of clinical investigation. DOI: 10.1172/JCI64502. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26075822/) 37. Zharikov A et al. (2019). Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration. Neurobiology of disease. DOI: 10.1016/j.nbd.2019.01.004. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30658149/) 38. Cole TA et al. (2021). α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. JCI insight. DOI: 10.1172/jci.insight.135633. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33682798/) 39. Mao X et al. (2016). Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (New York, N.Y.). DOI: 10.1126/science.aah3374. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27708076/) 40. Emmenegger M et al. (2021). LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies. EMBO molecular medicine. DOI: 10.15252/emmm.202114745. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34309222/) 41. Wegrzynowicz M et al. (2019). Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta neuropathologica. DOI: 10.1007/s00401-019-02023-x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31165254/) 42. Chen Y et al. (2019). Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. The European journal of neuroscience. DOI: 10.1111/ejn.14286. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30472757/) 43. Tanudjojo B et al. (2021). Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons. Nature communications. DOI: 10.1038/s41467-021-23682-z. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34155194/) 44. Kinet R et al. (2025). Differential pathological dynamics triggered by distinct Parkinson patient-derived α-synuclein extracts in nonhuman primates. Science advances. DOI: 10.1126/sciadv.adu6050. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40531987/) 45. Schmidt SI et al. (2025). Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons. NPJ Parkinson's disease. DOI: 10.1038/s41531-025-01038-4. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40541955/) 46. Kuan WL et al. (2023). Selective neurodegeneration generated by intravenous α-synuclein pre-formed fibril administration is not associated with endogenous α-synuclein levels in the rat brain. Brain pathology (Zurich, Switzerland). DOI: 10.1111/bpa.13128. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36321260/) 47. Fusco G et al. (2017). Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers. Science (New York, N.Y.). DOI: 10.1126/science.aan6160. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29242346/) 48. Cascella R et al. (2021). The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells. Nature communications. DOI: 10.1038/s41467-021-21937-3. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33753734/) 49. Gorbatyuk OS et al. (2010). In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Molecular therapy : the journal of the American Society of Gene Therapy. DOI: 10.1038/mt.2010.115. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20551914/) 50. Carmo-Gonçalves P et al. (2020). In Vitro Protective Action of Monomeric and Fibrillar α-Synuclein on Neuronal Cells Exposed to the Dopaminergic Toxins Salsolinol and DOPAL. ACS chemical neuroscience. DOI: 10.1021/acschemneuro.0c00527. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33080132/) 51. Pagano G et al. Trial of Prasinezumab in Early-Stage Parkinson's Disease. The New England journal of medicine. 2022. DOI: 10.1056/NEJMoa2202867; PMID: 35921451. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35921451/) 52. Pagano G et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nature medicine. 2024. DOI: 10.1038/s41591-024-02886-y; PMID: 38622249. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38622249/) 53. Pagano G et al. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nature medicine. 2024. DOI: 10.1038/s41591-024-03270-6; PMID: 39379705. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39379705/) 54. Nikolcheva T et al. Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study. Lancet (London, England). 2026. DOI: 10.1016/S0140-6736(26)00865-2; PMID: 42208564. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42208564/) 55. Lang AE et al. Trial of Cinpanemab in Early Parkinson's Disease. The New England journal of medicine. 2022. DOI: 10.1056/NEJMoa2203395; PMID: 35921450. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35921450/) 56. Hutchison RM et al. Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. Neurology. 2024. DOI: 10.1212/WNL.0000000000209137; PMID: 38315945. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38315945/) 57. Eijsvogel P et al. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial. Nature medicine. 2024. DOI: 10.1038/s41591-024-03101-8; PMID: 38902546. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38902546/) 58. Volc D et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. The Lancet. Neurology. 2020. DOI: 10.1016/S1474-4422(20)30136-8; PMID: 32562684. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32562684/) 59. Poewe W et al. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. Journal of Parkinson's disease. 2021. DOI: 10.3233/JPD-212594; PMID: 34092654. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34092654/) 60. Buur L et al. Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422. Movement disorders : official journal of the Movement Disorder Society. 2024. DOI: 10.1002/mds.29784; PMID: 38494847. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38494847/) 61. Shering C et al. Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50. Brain communications. 2025. DOI: 10.1093/braincomms/fcaf304; PMID: 40936651. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40936651/) 62. Liu Y et al. Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. The Journal of pharmacology and experimental therapeutics. 2025. DOI: 10.1124/jpet.124.002199; PMID: 39892989. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39892989/) 63. Schenk DB et al. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Movement disorders : official journal of the Movement Disorder Society. 2017. DOI: 10.1002/mds.26878; PMID: 27886407. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27886407/) 64. Brys M et al. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Movement disorders : official journal of the Movement Disorder Society. 2019. DOI: 10.1002/mds.27738; PMID: 31211448. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31211448/) 65. Jankovic J et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA neurology. 2018. DOI: 10.1001/jamaneurol.2018.1487; PMID: 29913017. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29913017/) ## Scope qualifiers | Qualifier | Determinable before outcome? | Determined from | Action | |---|---|---|---| | Dopaminergic neurons | yes | Defined cell identity and baseline regional/lineage markers, with independent survival assays | retained | | Parkinson's disease | yes | Baseline clinical/genetic/pathological setting, with diagnosis limits explicit | retained | No “responders,” post-treatment CSF-antibody-positive population, or outcome-defined susceptible group is inserted into the graded claim. Familial genotype and baseline seed/olfactory strata are evidence contexts, not retrospective exclusions of failed predictions. ## Independence basis SC1 Ζ uses human coding-change versus wild-type dosage natural experiments with different causal-assignment errors. The coding kindreds are not explained by a shared neighboring-locus multiplication; dosage disease is not explained by one mutation-specific altered sequence. Copy-number/expression confirmation and different kindreds narrow assignment artifacts. Shared family re-reports count once. Those lines support familial gene biology, not independent toxic-species mediation lines for SC4. PASADENA, SPARK, phase 1 reassays and PPMI-related reports have explicit cohort grouping. ## Citation ledger | # | Identifiers | Tier / kind | Status | Carries | Study/overlap ID | Access depth | Opened/status checked | |---|---|---|---|---|---|---|---| | 1 | PMID 9197268 / DOI 10.1126/science.276.5321.2045 | A / primary | none_found | C1 | SNCA_A53T_ITALIAN_GREEK_KINDREDS_1997 | abstract_metadata | 2026-10-03 | | 2 | PMID 14755719 / DOI 10.1002/ana.10795 | A / primary | none_found | C2 | SNCA_E46K_SPANISH_KINDRED_2004 | abstract_metadata | 2026-10-03 | | 3 | PMID 15451224 / DOI 10.1016/S0140-6736(04)17103-1 | A / primary | none_found | C3 | SNCA_FRENCH_DUPLICATION_KINDRED_2004 | abstract_metadata | 2026-10-03 | | 4 | PMID 15451225 / DOI 10.1016/S0140-6736(04)17104-3 | A / primary | none_found | C4 | SNCA_IBANEZ_DUPLICATION_FAMILIES_2004 | abstract_metadata | 2026-10-03 | | 5 | PMID 15159488 / DOI 10.1212/01.wnl.0000127517.33208.f4 | A / primary | none_found | C5 | SNCA_IOWA_TRIPLICATION_KINDRED | abstract_metadata | 2026-10-03 | | 6 | PMID 23404372 / DOI 10.1007/s00401-013-1096-7 | A / primary | none_found | C6 | SNCA_G51D_BRITISH_KINDRED_2013 | full_text_partial | 2026-10-03 | | 7 | PMID 23427326 / DOI 10.1212/WNL.0b013e31828727ba | A / primary | none_found | C7 | SNCA_H50Q_INDEX_CASE_2013 | abstract_metadata | 2026-10-03 | | 8 | PMID 29398121 / DOI 10.1016/j.neurobiolaging.2017.12.012 | A / primary | none_found | C8 | SNCA_H50Q_POPULATION_REASSESSMENT_2018 | abstract_metadata | 2026-10-03 | | 9 | PMID 29928688 / DOI 10.1038/s41531-018-0054-4 | A / primary | none_found | C9 | SNCA_IOWA_TRIPLICATION_KINDRED | full_text_partial | 2026-10-03 | | 10 | PMID 21412942 / DOI 10.1002/humu.21459 | A / primary | none_found | C10 | SNCA_FRENCH_DUPLICATION_KINDRED_2004 | abstract_metadata | 2026-10-03 | | 11 | PMID 23459986 / DOI 10.1001/jamaneurol.2013.172 | A / primary | none_found | C11 | PRKN_DOHERTY_FIVE_CASE_AUTOPSY_2013 | abstract_metadata | 2026-10-03 | | 12 | PMID 19735093 / DOI 10.1002/mds.22677 | A / primary | none_found | C12 | LRRK2_R1441G_MARTIMASSO_SINGLE_AUTOPSY_2009 | abstract_metadata | 2026-10-03 | | 13 | PMID 31235907 / DOI 10.1038/s41593-019-0423-2 | A / primary | none_found | C13 | SHAHMORADIAN_LEWY_ULTRASTRUCTURE_2019 | abstract_metadata | 2026-10-03 | | 14 | PMID 19286695 / DOI 10.1093/brain/awp044 | A / primary | none_found | C14 | GBA_UK_NEUMANN_CLINICAL_AUTOPSY_2009 | abstract_metadata | 2026-10-03 | | 15 | PMID 19846850 / DOI 10.1056/NEJMoa0901281 | A / primary | none_found | C15 | GBA_SIDRANSKY_MULTICENTER_CASECONTROL_2009 | abstract_metadata | 2026-10-03 | | 16 | PMID 29917054 / DOI 10.1093/brain/awy157 | A / primary | none_found | C16 | MOKRETAR_SNCA_SOMATIC_NIGRA_FISH_2018 | abstract_metadata | 2026-10-03 | | 17 | PMID 37059509 / DOI 10.1016/S1474-4422(23)00109-6 | A / primary | none_found | C17 | PPMI_CSF_SAA_PROGRAM | abstract_metadata | 2026-10-03 | | 18 | PMID 40314782 / DOI 10.1007/s00401-025-02871-w | A / primary | none_found | C18 | JENSEN_UK_LRRK2_VARIANT_PLA_AUTOPSY_2025 | full_text_partial | 2026-10-03 | | 19 | PMID 39613827 / DOI 10.1038/s41531-024-00841-9 | A / primary | none_found | C19 | JENSEN_SYDNEY_HUMAN_PLA_AUTOPSY_2024 | full_text_partial | 2026-10-03 | | 20 | PMID 40541208 / DOI 10.1016/S1474-4422(25)00157-7 | A / primary | none_found | C20 | PPMI_CSF_SAA_PROGRAM | abstract_metadata | 2026-10-03 | | 21 | PMID 42806694 / DOI 10.1002/mds.70553 | A / primary | none_found | C21 | NORWAY_LRRK2_SAA_PLUS_PPMI_PROGRAM_2026 | abstract_metadata | 2026-10-03 | | 22 | PMID 42258190 / DOI 10.1001/jamaneurol.2026.1634 | A / primary | none_found | C22 | MDGAP_GP2_MULTIBRAINBANK_AUTOPSY_2026 | full_text_partial | 2026-10-03 | | 23 | PMID 42660007 / DOI 10.1016/j.parkreldis.2026.108955 | A / primary | none_found | C23 | SNCA_G51D_AUSTRALIAN_KINDRED_2026 | abstract_metadata | 2026-10-03 | | 24 | PMID 33307186 / DOI 10.1016/j.nbd.2020.105182 | A / primary | none_found | C24 | UKBIOBANK_RARE_SNCA_COPYVARIANTS_2021 | abstract_metadata | 2026-10-03 | | 25 | PMID 11532993 / DOI 10.1093/hmg/10.17.1847 | A / primary | none_found | C25 | SNCA_COMMON_HAPLOTYPES_CASECONTROL_2001 | abstract_metadata | 2026-10-03 | | 26 | PMID 21325059 / DOI 10.1073/pnas.1100976108 | A / primary | none_found | C26 | Winner2011_21325059 | full_text_partial | 2026-10-03 | | 27 | PMID 19745811 / DOI 10.1038/emboj.2009.257 | A / primary | none_found | C27 | Karpinar2009_19745811 | abstract_metadata | 2026-10-03 | | 28 | PMID 12042811 / DOI 10.1038/nm0602-600 | A / primary | none_found | C28 | Xu2002_12042811 | abstract_metadata | 2026-10-03 | | 29 | PMID 19409267 / DOI 10.1016/j.neuron.2009.01.033 | A / primary | none_found | C29 | Mosharov2009_19409267 | full_text_partial | 2026-10-03 | | 30 | PMID 23161999 / DOI 10.1126/science.1227157 | A / primary | none_found | C30 | Luk2012_23161999 | full_text_partial | 2026-10-03 | | 31 | PMID 21982369 / DOI 10.1016/j.neuron.2011.08.033 | A / primary | none_found | C31 | Volpicelli-Daley2011_21982369 | abstract_metadata | 2026-10-03 | | 32 | PMID 32075919 / DOI 10.1073/pnas.1913904117 | A / primary | none_found | C32 | Mahul-Mellier2020_32075919 | full_text_partial | 2026-10-03 | | 33 | PMID 29487216 / DOI 10.1073/pnas.1713849115 | A / primary | none_found | C33 | Grassi2018_29487216 | abstract_metadata | 2026-10-03 | | 34 | PMID 12376616 / DOI 10.1073/pnas.172514599 | A / primary | none_found | C34 | Dauer2002_12376616 | abstract_metadata | 2026-10-03 | | 35 | PMID 29497361 / DOI 10.3389/fnmol.2018.00036 | A / primary | none_found | C35 | Benskey2018_29497361 | abstract_metadata | 2026-10-03 | | 36 | PMID 26075822 / DOI 10.1172/JCI64502 | A / primary | none_found | C36 | Zharikov2015_26075822 | full_text_partial | 2026-10-03 | | 37 | PMID 30658149 / DOI 10.1016/j.nbd.2019.01.004 | A / primary | none_found | C37 | Zharikov2019_30658149 | full_text_partial | 2026-10-03 | | 38 | PMID 33682798 / DOI 10.1172/jci.insight.135633 | A / primary | none_found | C38 | Cole2021_33682798 | full_text_partial | 2026-10-03 | | 39 | PMID 27708076 / DOI 10.1126/science.aah3374 | A / primary | none_found | C39 | Mao2016_27708076 | full_text_partial | 2026-10-03 | | 40 | PMID 34309222 / DOI 10.15252/emmm.202114745 | A / primary | none_found | C40 | Emmenegger2021_34309222 | full_text_partial | 2026-10-03 | | 41 | PMID 31165254 / DOI 10.1007/s00401-019-02023-x | A / primary | none_found | C41 | Wegrzynowicz2019_31165254 | full_text_partial | 2026-10-03 | | 42 | PMID 30472757 / DOI 10.1111/ejn.14286 | A / primary | none_found | C42 | Chen2019_30472757 | abstract_metadata | 2026-10-03 | | 43 | PMID 34155194 / DOI 10.1038/s41467-021-23682-z | A / primary | none_found | C43 | Tanudjojo2021_34155194 | full_text_partial | 2026-10-03 | | 44 | PMID 40531987 / DOI 10.1126/sciadv.adu6050 | A / primary | none_found | C44 | Kinet2025_40531987 | full_text_partial | 2026-10-03 | | 45 | PMID 40541955 / DOI 10.1038/s41531-025-01038-4 | A / primary | none_found | C45 | Schmidt2025_40541955 | full_text_partial | 2026-10-03 | | 46 | PMID 36321260 / DOI 10.1111/bpa.13128 | A / primary | none_found | C46 | Kuan2023_36321260 | abstract_metadata | 2026-10-03 | | 47 | PMID 29242346 / DOI 10.1126/science.aan6160 | A / primary | none_found | C47 | Fusco2017_29242346 | abstract_metadata | 2026-10-03 | | 48 | PMID 33753734 / DOI 10.1038/s41467-021-21937-3 | A / primary | none_found | C48 | Cascella2021_33753734 | abstract_metadata | 2026-10-03 | | 49 | PMID 20551914 / DOI 10.1038/mt.2010.115 | A / primary | none_found | C49 | Gorbatyuk2010_20551914 | full_text_partial | 2026-10-03 | | 50 | PMID 33080132 / DOI 10.1021/acschemneuro.0c00527 | A / primary | none_found | C50 | Carmo-Gonçalves2020_33080132 | abstract_metadata | 2026-10-03 | | 51 | PMID 35921451 / DOI 10.1056/NEJMoa2202867 | A / rct | none_found | C51 | NCT03100149 | abstract_metadata | 2026-10-03 | | 52 | PMID 38622249 / DOI 10.1038/s41591-024-02886-y | A / primary | none_found | C52 | NCT03100149 | full_text_partial | 2026-10-03 | | 53 | PMID 39379705 / DOI 10.1038/s41591-024-03270-6 | A / rct | none_found | C53 | NCT03100149 | full_text_partial | 2026-10-03 | | 54 | PMID 42208564 / DOI 10.1016/S0140-6736(26)00865-2 | A / rct | erratum: PMID 42392102; DOI 10.1016/S0140-6736(26)01301-2; appendix corrected as of 2026-07-02; correction body read; corrected appendix not examined, detailed scientific impact unresolved. | C54 | NCT04777331 | abstract_metadata | 2026-10-03 | | 55 | PMID 35921450 / DOI 10.1056/NEJMoa2203395 | A / rct | none_found | C55 | NCT03318523 | abstract_metadata | 2026-10-03 | | 56 | PMID 38315945 / DOI 10.1212/WNL.0000000000209137 | A / rct | none_found | C56 | NCT03318523 | abstract_metadata | 2026-10-03 | | 57 | PMID 38902546 / DOI 10.1038/s41591-024-03101-8 | A / rct | none_found | C57 | NCT04075318 | full_text_partial | 2026-10-03 | | 58 | PMID 32562684 / DOI 10.1016/S1474-4422(20)30136-8 | A / rct | none_found | C58 | PD01A-program:EudraCT2011-002650-31/2013-001774-20/2014-002489-54/2015-004854-16 | abstract_metadata | 2026-10-03 | | 59 | PMID 34092654 / DOI 10.3233/JPD-212594 | A / rct | none_found | C59 | PD03A-EudraCT2014-000568-16 | full_text_partial | 2026-10-03 | | 60 | PMID 38494847 / DOI 10.1002/mds.29784 | A / rct | none_found | C60 | NCT03611569 | abstract_metadata | 2026-10-03 | | 61 | PMID 40936651 / DOI 10.1093/braincomms/fcaf304 | A / primary | none_found | C61 | NCT03272165+NCT04449484 | full_text_partial | 2026-10-03 | | 62 | PMID 39892989 / DOI 10.1124/jpet.124.002199 | A / primary | none_found | C62 | NCT02459886 | abstract_metadata | 2026-10-03 | | 63 | PMID 27886407 / DOI 10.1002/mds.26878 | A / rct | none_found | C63 | NCT02095171 | abstract_metadata | 2026-10-03 | | 64 | PMID 31211448 / DOI 10.1002/mds.27738 | A / rct | none_found | C64 | NCT02459886 | full_text_partial | 2026-10-03 | | 65 | PMID 29913017 / DOI 10.1001/jamaneurol.2018.1487 | A / rct | none_found | C65 | NCT02157714 | abstract_metadata | 2026-10-03 | ## Claim register | ID | Bounded examined result | Load-bearing for | Sources | Verification | |---|---|---|---|---| | C1 | An SNCA mutation was identified in a large Italian kindred and three Greek families with autosomal dominant Parkinson disease. The human segregation/natural-experiment result connects altered alpha-synuclein biology to inherited disease. | SC1 | 1 | verified against abstract_metadata | | C2 | E46K segregated in a Spanish autosomal dominant parkinsonism/dementia family: affected members and three young asymptomatic carriers had the variant, while examined controls did not. Autopsy showed severe substantia nigra atrophy and abundant alpha-synuclein Lewy pathology without Alzheimer pathology. | SC1 | 2 | verified against abstract_metadata | | C3 | Screening nine autosomal dominant families found an SNCA duplication in one family, confirmed by fluorescence in situ hybridization. The phenotype was relatively late-onset and slowly progressive, contrasting with the previously described severe triplication phenotype. | SC1 | 3 | verified against abstract_metadata | | C4 | Screening 119 people with familial Parkinson disease identified two SNCA duplications. Carriers had a phenotype resembling typical PD, rather than the fulminant triplication phenotype. | SC1 | 4 | verified against abstract_metadata | | C5 | In the Iowa triplication kindred, blood alpha-synuclein and brain SNCA mRNA were approximately doubled. Brain insoluble/aggregated alpha-synuclein was disproportionately increased relative to the net soluble signal. | SC1 | 5 | verified against abstract_metadata | | C6 | G51D segregated in a British family and was absent in more than 4500 controls; larger SNCA rearrangements were excluded. The autopsied proband had onset at 19, severe nigral and widespread neuronal loss, neuronal alpha-synuclein inclusions and MSA-like oligodendroglial inclusions. Tau and TDP-43 copathology were also present. | SC1 | 6 | verified against full_text_partial | | C7 | The original report identified H50Q in one neuropathologically confirmed PD case and nominated it as a new SNCA missense variant. | SC1 | 7 | verified against abstract_metadata | | C8 | Primary population/case-control reanalysis of nominated SNCA mutations found H50Q in large population resources and no enrichment in PD, leading the authors to conclude that H50Q is probably not pathogenic. | SC1 | 8 | verified against abstract_metadata | | C9 | A descendant of the Iowa kindred developed parkinsonism at 41, severe cognitive decline and widespread Lewy pathology with severe substantia nigra loss. High-resolution arrays mapped a 1.7 Mb triplication, with 12 genes including SNCA and breakpoints disrupting HERC6 and CCSER1. Comparative mapping included a distinct Lister triplication case. | SC1 | 9 | verified against full_text_partial | | C10 | A previously known duplication kindred was characterized with a 4.928 Mb duplicated interval containing 31 genes. SNCA and 13 other genes had increased mRNA in studied cells. Dopamine-transporter imaging was associated with clinical disease severity. | SC1 | 10 | verified against abstract_metadata | | C11 | Five unrelated compound-heterozygous parkin cases were compared with five pathologically confirmed PD cases and four controls, matched first by age at death. Nigral neuronal loss was as severe as in PD, with relatively preserved dorsal tier; sparse Lewy bodies appeared in two of five parkin cases. Cognitive impairment was absent. | SC4 | 11 | verified against abstract_metadata | | C12 | One R1441G LRRK2 patient had onset at 68, an 18-year levodopa-responsive course and mild nigral neuronal loss at autopsy without Lewy bodies/neurites or cytoplasmic alpha-synuclein, tau, LRRK2 or ubiquitin inclusions by the reported examination. | SC4 | 12 | verified against abstract_metadata | | C13 | Correlative light/electron microscopy and tomography in human PD tissue showed alpha-synuclein-positive Lewy pathology crowded with membranes, vesicles and dysmorphic organelles; filaments were observed in many but not all inclusions. Super-resolution microscopy and lipid measurements supported lipid enrichment. | SC2, SC4 | 13 | verified against abstract_metadata | | C14 | GBA mutations occurred in 33/790 British PD cases and 3/257 controls (OR3.7,95%CI 1.12–12.14). All 17 examined mutation-carrier autopsies had widespread alpha-synuclein pathology (Braak 5–6); cognitive impairment/dementia and hallucinations were frequent clinical features. | SC4 | 14 | verified against abstract_metadata | | C15 | An original 16-center study of 5691 PD cases and 4898 controls found a strong GBA mutation association with PD (OR5.43). Broader sequencing detected mutations missed by testing only the two common alleles, including about 7% of non-Ashkenazi PD cases. | SC4 | 15 | verified against abstract_metadata | | C16 | Blinded SNCA FISH examined 40 sporadic PD brains,5 MSA brains and 25 controls. PD cases had a higher mean fraction of dopaminergic neurons with gains (0.78%vs 0.45%,P=.017); gains were inversely associated with onset age. Authors explicitly allowed either risk-factor or disease-consequence explanations. | SC1, SC4 | 16 | verified against abstract_metadata | | C17 | Cross-sectional PPMI analysis included 1123 participants:545 PD,163 controls,54 without dopaminergic deficit,51 prodromal and 310 nonmanifesting carriers. CSF SAA sensitivity for PD was 87.7% and control specificity 96.3%; LRRK2-PD positivity was 67.5% and fell to 34.7% with normal olfaction.44/51 prodromal participants were positive. | SC4 | 17 | verified against abstract_metadata | | C18 | MJF-14 PLA found non-inclusion particulate signal in all six Lewy-negative LRRK2-variant brains, compared with five Lewy-body-disease brains and six controls. Crucially, the six comprise three clinicalPD cases, one neuropathologically confirmedPSP case and two people without clinical neurodegenerative diagnoses. Signals often involved pontocerebellar/inferior-olivary regions. | SC2, SC4 | 18 | verified against full_text_partial | | C19 | Human component compared anterior cingulate tissue from 10 BraakIV PD,10 BraakVI PD and 10 controls, plus 2 DLB and 2 controls for selected analyses. PLA revealed abundant non-inclusion signal in both PD groups without a significant IV–VI difference. Neuron counts per sampled region did not significantly differ (P=.103); inference of earlier pathology derives from cross-sectional staging. | SC2, SC4 | 19 | verified against full_text_partial | | C20 | Longitudinal analysis included 1631 participants across UK, PPMI and Tuebingen cohorts. Faster CSF amplification kinetics predicted cognitive decline (MoCA≤21): PPMIHR2.36(95%CI 1.60–3.46) and TuebingenHR2.17(1.07–4.41). The abstract states this prognostic association for cognition, not every progression endpoint. | SC4 | 20 | verified against abstract_metadata | | C21 | The Norwegian cohort had 76 LRRK2 carriers,714 idiopathicPD and 411 controls, but CSF SAA measured only 10 LRRK2-PD,30 nonmanifesting carriers,6 controls and 56 idiopathicPD.80% of LRRK2-PD and one unaffected carrier were positive. Exploratory mitochondrial genetic burden association also used a PPMI replication component. | SC4 | 21 | verified against abstract_metadata | | C22 | Original retrospective clinicopathologic/genetic analysis included 3353 eligible donors from 11 brain banks. PD/PDD/DLB clinical diagnoses had 92.0% positive predictive value for Lewy pathology;33/745 neurologically normal controls had Lewy pathology. AD copathology occurred in 426/1064 Lewy-disease cases; GBA1 carriers had more extensive Lewy burden than noncarriers/LRRK2 carriers. | SC4 | 22 | verified against full_text_partial | | C23 | An Australian G51D kindred showed young-onset parkinsonism and variable expression: proband motor onset 38 and cognitive symptoms 41, sisters onset 51 and 28, and a 27-year-old carrier with subtle thumb tremor. Proband autopsy showed diffuse Lewy pathology. | SC1 | 23 | verified against abstract_metadata | | C24 | UKBiobank screening of about 500000 people identified 30 SNCA copy-number events (6 duplications,6 deletions,18 complex events), many suspected mosaic. None had diagnosedPD at the reported follow-up; three had some prodromal features without meeting prodromal criteria. Seven of 18 complex events had blood cancer. | SC1 | 24 | verified against abstract_metadata | | C25 | Original case-control haplotype analysis found common SNCA haplotypes associated with Parkinson disease, extending locus relevance beyond rare Mendelian coding/copy-number families. | SC4 | 25 | verified against abstract_metadata | | C26 | Oligomer-promoting variants cause greater dopaminergic neuronal loss than fast fibril-forming variants. NeuN comparisons support actual loss; even weaker-promoter expression exceeded familial triplication levels, and unrelated HET-s aggregates were not similarly toxic. | SC2, SC3, SC4 | 26 | verified against full_text_partial | | C27 | Prefibrillar variants associate with increased neuronal toxicity and behavioral defects across model systems. | SC2, SC3, SC4 | 27 | verified against abstract_metadata | | C28 | Dopaminergic apoptosis depends on endogenous dopamine and ROS; soluble alpha-syn/14-3-3 complexes are implicated, whereas cortical neurons show protection. | SC2, SC3, SC4 | 28 | verified against abstract_metadata | | C29 | Snca deletion protects against L-DOPA-induced death without reducing cytosolic dopamine; calcium/dopamine differences confer SN susceptibility. | SC2, SC3, SC4 | 29 | verified against full_text_partial | | C30 | Seeded pathology progresses with selective SNpc dopamine-neuron loss, reduced dopamine and motor deficits, while adjacent VTA is spared. PBS/monomer and Snca-null recipients lack the same pathology/DA-loss outcome; not all gross/open-field motor outcomes change. | SC2, SC3, SC4 | 30 | verified against full_text_partial | | C31 | PFFs recruit native alpha-syn into Lewy-like pathology with synaptic/electrical deficits and later neuronal death. | SC2, SC3, SC4 | 31 | verified against abstract_metadata | | C32 | Inclusion maturation coincides with organelle sequestration, mitochondrial/synaptic disruption and later death beyond early fibrillization. Snca-null cultures do not show PFF-associated death; glial TUNEL precedes later neuronal NeuN/TUNEL death. | SC2, SC3, SC4 | 32 | verified against full_text_partial | | C33 | Incomplete aggregate degradation generates a distinct nonfibrillar fragment associated with mitochondrial damage, energetic stress and mitophagy. | SC2, SC3, SC4 | 33 | verified against abstract_metadata | | C34 | Knockout resists dopamine-neuron degeneration; resistance tracks inability of MPTP to inhibit complex I rather than abnormal dopamine-transporter function. | SC2, SC3, SC4 | 34 | verified against abstract_metadata | | C35 | Suppression precedes MHC-I induction, microglial/T-cell recruitment and later nigrostriatal neuronal loss; control hairpin/cerebellar exposure does not reproduce injury. | SC2, SC3, SC4 | 35 | verified against abstract_metadata | | C36 | Partial knockdown is tolerated at baseline and protects rotenone-exposed nigral neurons/terminals while attenuating motor deficits. Blinded counts co-label TH, MAP2 and nuclei; functional/neuritic protection accompanies counts. | SC2, SC3, SC4 | 36 | verified against full_text_partial | | C37 | Strong long-term knockdown shows no Nissl-defined neuron loss or significant motor dysfunction; TH declines with both vectors. | SC2, SC3, SC4 | 37 | verified against full_text_partial | | C38 | ASOs reduce pathology and preserve TH-positive counts; some pretreatment paradigms normalize dopamine. Transient post-seed treatment later preserves TH despite increased aggregate counts. | SC2, SC3, SC4 | 38 | verified against full_text_partial | | C39 | Lag3 loss delays PFF-associated dopaminergic loss and biochemical/behavioral deficits. In vivo TH/Nissl stereology and dopamine/motor outcomes improve; cultured KO-to-re-expression rescue, PI/NeuN and calcium assays strengthen a model-specific uptake-to-injury dependency. | SC2, SC3, SC4 | 39 | verified against full_text_partial | | C40 | No neuronal expression detected; inducible LAG3 does not increase human-culture seeding, knockout does not change A53T survival or slice pathology. | SC2, SC3, SC4 | 40 | verified against full_text_partial | | C41 | Aggregation-profile modulation restores dopamine release and preserves TH counts/gait; baseline nigral degeneration is NeuN-confirmed. Dense clusters/HMW signal decrease while dispersed small species increase. | SC2, SC3, SC4 | 41 | verified against full_text_partial | | C42 | Reduced/absent SNCA alleles resist pS129 Lewy-like pathology. | SC2, SC3, SC4 | 42 | verified against abstract_metadata | | C43 | Brain-amplified strains produce dose/strain-dependent death in triplication neurons, reversed by isogenic dosage normalization. Similar early seeding does not imply equal later toxicity. | SC1, SC2, SC3, SC4 | 43 | verified against full_text_partial | | C44 | Equal-total-alpha-syn LA/SA patient fractions yield different time courses and similar later TH-defined nigrostriatal deficits. SA contains small amyloid assemblies, so its former noLB label does not mean no pathological alpha-syn. | SC2, SC3, SC4 | 44 | verified against full_text_partial | | C45 | Parkin deficiency increases native aggregated/released/seeding-competent alpha-syn and synaptic/Ca2+ abnormalities, including dopamine-neuronal and astrocytic aggregates. | SC2, SC3, SC4 | 45 | verified against full_text_partial | | C46 | Specific midbrain dopamine and other neuronal populations are lost, without association to region-level native alpha-syn expression. | SC2, SC3, SC4 | 46 | verified against abstract_metadata | | C47 | Lipophilic membrane interaction and bilayer insertion define toxic oligomer properties; targeted mutation reduces cellular toxicity. | SC2, SC3, SC4 | 47 | verified against abstract_metadata | | C48 | Fibrils release toxic soluble oligomers; shorter fibrils cause greater immediate dysfunction consistent with more ends. | SC2, SC3, SC4 | 48 | verified against abstract_metadata | | C49 | Suppression produces marker-confirmed cell loss, striatal dopamine depletion and behavioral asymmetry; protein re-expression partially reverses injury. | SC2, SC3, SC4 | 49 | verified against full_text_partial | | C50 | Monomer protects against both catechols; fibrils improve DOPAL but not salsolinol viability, with potentially less-toxic DOPAL adduct formation. | SC2, SC3, SC4 | 50 | verified against abstract_metadata | | C51 | PASADENA randomized 316 early PD participants; neither prasinezumab dose met the global MDS-UPDRS primary endpoint, and dopamine-transporter imaging did not differ substantially from placebo. | SC3, SC4 | 51 | verified against abstract_metadata | | C52 | Exploratory analyses of PASADENA baseline-defined subpopulations found a larger numerical motor-sign effect in groups expected to progress faster. | SC3, SC4 | 52 | verified against full_text_partial | | C53 | PASADENA open-label extension participants had slower motor-score deterioration than a weighted external PPMI comparator over four years. | SC3, SC4 | 53 | verified against full_text_partial | | C54 | PADOVA randomized 586 early PD participants on stable symptomatic medication; the primary motor-event endpoint was not met (HR 0.84, 95% CI 0.69–1.01; p=0.066), with prespecified exploratory signals favoring further study. | SC3, SC4 | 54 | verified against abstract_metadata | | C55 | SPARK randomized 357 early PD participants; no cinpanemab dose improved clinical progression or DaT-SPECT versus placebo, and the trial was stopped for lack of efficacy. | SC3, SC4 | 55 | verified against abstract_metadata | | C56 | SPARK biomarker analyses confirmed seeds in most of the baseline CSF subgroup, but neither clinical nor imaging/fluid biomarkers showed a cinpanemab treatment effect. | SC3, SC4 | 56 | verified against abstract_metadata | | C57 | UB-312 phase 1 PD vaccination induced antibodies in serum and a subset of CSF samples; exploratory seed-amplification maximum fluorescence fell in one active dose group. Randomized groups did not differ statistically on clinical scales. | SC3, SC4 | 57 | verified against full_text_partial | | C58 | PD01A dose-randomized phase 1 PD immunization and extensions showed a humoral response that could be reactivated with booster dosing and acceptable tolerability over follow-up. | SC3 | 58 | verified against abstract_metadata | | C59 | PD03A placebo-controlled phase 1 PD vaccination generated anti-peptide and alpha-synuclein-specific antibodies with acceptable tolerability. | SC3 | 59 | verified against full_text_partial | | C60 | Single-dose Lu AF82422 reduced plasma free alpha-synuclein and the CSF free-to-total ratio in the high-dose PD cohort, supporting central compartment engagement. | SC3 | 60 | verified against abstract_metadata | | C61 | MEDI1341 randomized phase 1 healthy and PD studies measured dose-dependent lowering of CSF free alpha-synuclein; the highest PD dose reduced the median CSF-free signal by 59.0% at Day85. | SC3 | 61 | verified against full_text_partial | | C62 | Crosslink-stabilized assays of cinpanemab phase 1 samples directly detected dose- and time-dependent drug–alpha-synuclein complexes in human CSF. | SC3 | 62 | verified against abstract_metadata | | C63 | Single-dose PRX002 in healthy participants produced dose-dependent reductions of free serum alpha-synuclein with favorable phase 1 tolerability. | SC3 | 63 | verified against abstract_metadata | | C64 | Cinpanemab phase 1 healthy/PD study measured dose-proportional exposure and plasma complexes; CSF drug levels were a small fraction of serum levels. | SC3 | 64 | verified against full_text_partial | | C65 | Multiple-dose PRX002 in PD reduced free serum alpha-synuclein and produced dose-dependent CSF drug exposure with generally favorable phase 1 tolerability. | SC3 | 65 | verified against abstract_metadata | *Generated with the exact HSEF Hypothesis Review v5.3 framework. Companion scorecard and raw primary-source records preserve provenance; validation status is updated only after the archived validator succeeds.* ### Consensus consistency validation — 9 October 2026 Consensus browser Pro and connector discovery and fetched paper records were reconciled with independently retrieved original PubMed primary abstracts/status records. The exact query and three fetched records are retained with the consistency audit. This supplementary check used the prior grade visibly; it is not a blind re-score and is not covered by the earlier adversarial approval. - PASADENA, PMID 35921451, DOI 10.1056/NEJMoa2202867: original Results confirm neither dose improved the global primary outcome or dopamine-transporter imaging meaningfully. This agrees with E51/[51]. Lack of benefit does not establish removal of the intracellular toxic species or disprove every alpha-synuclein mechanism. - SPARK, PMID 35921450, DOI 10.1056/NEJMoa2203395: original Results confirm no clinical or imaging advantage and stopping for lack of efficacy. This agrees with E55/[55]; it is a separate trial from PASADENA. - PASADENA extension, PMID 39379705, DOI 10.1038/s41591-024-03270-6: the original abstract describes a favorable exploratory comparison against external PPMI participants. This agrees with E53/[53]. It remains part of NCT03100149, not independent randomized confirmation; publication-type metadata does not make the extension contrast randomized. **Assessment after reconciliation:** Γ / Moderate held, with SC1 Ζ and SC2–SC4 Γ. All three sources were already in the 65-report inventory; the supplementary check adds zero primary reports or independent causal lines. Source access for this check is abstract/status depth, not a complete-paper audit. The unchanged human-scope blocker is selective toxic-species mediation and generalization, rather than simply counting negative trials. The supplementary Pro thread is preserved verbatim: [Alpha-synuclein Parkinson causality](https://consensus.app/search/alpha-synuclein-parkinson-causality/HQ86Wa25Rl6VsUDvHSlliw/). Provider syntheses and full-text badges do not establish source access by this reviewer; the matched original-source checks above determine credit. This dated supplement adds source reconciliation to the original review. Its original narrative, registered scope, source inventory, grades and any earlier approval remain historical records; the earlier approval does not certify this supplement. New sources described here are supplemental and are not counted in the original inventory.